Long on Meds

References and Evidence Library

Evidence organized by medication class and pathway.

The Long on Meds evidence library contains 452 references organized into 9 major sections and 76 expandable evidence groups.

How to use this page

Open a major section, then open any evidence group to review the citations supporting the Long on Meds medication-pathway framework. The library is organized so readers can inspect the evidence without facing one long wall of citations.

Cardiovascular Medications70 references
Statins9 references
  1. Sabeel S, Motaung B, Nguyen KA, et al. Impact of Statins as Immune-Modulatory Agents on Inflammatory Markers in Adults With Chronic Diseases: ASystematic Review and Meta-Analysis. PLoS One. 2024.Supports statin effects on inflammatory markers including CRP, IL-6, and TNF-α.
  2. Woźniak E, Broncel M, Niedzielski M, Woźniak A, Gorzelak-Pabiś P. The Effect of Lipid-Lowering Therapies on the Pro-Inflammatory and Anti-Inflammatory Properties of Vascular Endothelial Cells. PLoS One. 2023.Supports endothelial anti-inflammatory effects of lipid-lowering therapy.
  3. Barale C, Frascaroli C, Senkeev R, Cavalot F, Russo I. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. BioMed Research International. 2018.Supports statin effects on inflammation and platelet activation.
  4. Zhao TX, Mallat Z. Targeting the Immune System in Atherosclerosis: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019.Supports the role of inflammatory pathways in atherosclerosis and the rationale for immune-modulating cardiovascular therapy.
  5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21):2195-2207.JUPITER trial; supports rosuvastatin in patients with elevated hsCRP and provides major clinical outcome evidence.
  6. Kandelouei T, Abbasifard M, Imani D, et al. Effect of Statins on Serum Level of hs-CRP and CRP in Patients With Cardiovascular Diseases: ASystematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators of Inflammation. 2021;2021:5711321.Supports statin-related CRP reduction across randomized trials.
  7. Tousoulis D, Psarros C, Demosthenous M, et al. Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease: The Emerging Role of Statins. Journal of the American College of Cardiology. 2014;63(23):2491-2502.Supports statin effects on vascular inflammation and NF-κB-related inflammatory biology.
  8. Xie S, Galimberti F, Olmastroni E, et al. Effect of Lipid-Lowering Therapies on C-Reactive Protein Levels: A Comprehensive Meta-Analysis of Randomized Controlled Trials. Cardiovascular Research. 2024.Supports CRP reduction with lipid-lowering therapies.
  9. van der Meij E, Koning GG, Vriens PW, et al. A Clinical Evaluation of Statin Pleiotropy: Statins Selectively and Dose-Dependently Reduce Vascular Inflammation. PLoS One. 2013.Supports dose-dependent vascular anti-inflammatory effects of statins.
Angiotensin Receptor Blockers12 references
  1. Awad K, Zaki MM, Mohammed M, et al. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: ASystematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clinic Proceedings. 2022;97(10):1808-1823.Supports anti-inflammatory effects of ACE inhibitors and ARBs on CRP, IL-6, and TNF-α.
  2. Krämer C, Sunkomat J, Witte J, et al. Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179. Circulation Research. 2002;90(7):770-776.Supports losartan’s EXP3179 metabolite as a non-AT1 anti-inflammatory mechanism.
  3. Kim JM, Heo HS, Choi YJ, et al. Inhibition of NF-κB-Induced Inflammatory Responses by Angiotensin II Antagonists in Aged Rat Kidney. Experimental Gerontology. 2011;46(7):542-548.Supports ARB-related NF-κB suppression in aging tissue.
  4. Shen L, Mo H, Cai L, et al. Losartan Prevents Sepsis-Induced Acute Lung Injury and Decreases Activation of Nuclear Factor KappaB and Mitogen-Activated Protein Kinases. Shock. 2009;31(5):500-506.Supports losartan effects on NF-κB and MAPK inflammatory signaling.
  5. Saber S, Mahmoud AAA, Goda R, et al. Perindopril, Fosinopril and Losartan Inhibited the Progression of Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice via the Inactivation of Nuclear Transcription Factor Kappa-B. Toxicology Letters. 2018;295:32-40.Supports losartan and renin-angiotensin-system drug effects on NF-κB signaling.
  6. Pang T, Benicky J, Wang J, et al. Telmisartan Ameliorates Lipopolysaccharide-Induced Innate Immune Response Through Peroxisome Proliferator-Activated Receptor-γ Activation in Human Monocytes. Journal of Hypertension. 2012.Supports telmisartan’s PPARγ-mediated anti-inflammatory activity.
  7. Yano Y, Hoshide S, Ishikawa J, et al. The Differential Effects of Angiotensin II Type 1 Receptor Blockers on Microalbuminuria in Relation to Low-Grade Inflammation in Metabolic Hypertensive Patients. American Journal of Hypertension. 2007.Supports within-class ARB differences in relation to low-grade inflammation.
  8. Nakayama S, Watada H, Mita T, et al. Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics With Hypertension. Hypertension Research. 2008.Supports comparison of ARBs in metabolic hypertension.
  9. Fortuño A, Bidegain J, Robador PA, et al. Losartan Metabolite EXP3179 Blocks NADPH Oxidase-Mediated Superoxide Production by Inhibiting Protein Kinase C: Potential Clinical Implications in Hypertension. Hypertension. 2009.Supports losartan metabolite effects on NADPH oxidase and oxidative stress.
  10. An J, Nakajima T, Kuba K, Kimura A. Losartan Inhibits LPS-Induced Inflammatory Signaling Through a PPARγ-Dependent Mechanism in Human THP-1 Macrophages. Hypertension Research. 2010.Supports losartan effects on macrophage inflammatory signaling.
  11. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study: A Randomised Trial Against Atenolol. Lancet. 2002;359(9311):995-1003.LIFE trial; supports losartan cardiovascular outcome benefit compared with atenolol.
  12. Katsiki N, Tsioufis K, Ural D, Volpe M. Fifteen Years of LIFE: Lessons Learned for Losartan. Journal of Clinical Hypertension. 2018.Review of LIFE trial implications and losartan’s clinical role.
ACE Inhibitors4 references
  1. Awad K, Zaki MM, Mohammed M, et al. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: ASystematic Review and Meta-Analysis of Randomized Controlled Trials. Mayo Clinic Proceedings. 2022;97(10):1808-1823.Core ACE inhibitor and ARB meta-analysis; supports RAS inhibitors and inflammatory marker reduction.
  2. Desideri G, Grassi D, Croce G, et al. Different Effects of Angiotensin Converting Enzyme Inhibitors on Endothelin-1 and Nitric Oxide Balance in Human Vascular Endothelial Cells: Evidence of an Oxidant-Sensitive Pathway. Mediators of Inflammation. 2008.Supports ACE inhibitor effects on endothelial oxidative and nitric oxide pathways.
  3. Krysiak R, Okopień B. Different Effects of Perindopril and Enalapril on Monocyte Cytokine Release in Coronary Artery Disease Patients With Normal Blood Pressure. Pharmacological Reports. 2013.Supports within-class ACE inhibitor differences in monocyte cytokine release.
  4. Krysiak R, Okopień B. Lymphocyte-Suppressing Action of Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease Patients With Normal Blood Pressure. Pharmacological Reports. 2011.Supports ACE inhibitor immunomodulatory activity.
Beta-Blockers10 references
  1. Kajaia N, Enukidze M, Machavariani M, et al. Modulation of Inflammatory and Adrenergic Pathways in Hypertension: Effects of β-Blockers on Cytokine Release in Jurkat T Cells. Acta Biochimica Polonica. 2025.Supports beta-blocker effects on cytokine release and adrenergic-inflammatory pathways.
  2. Wolf SC, Sauter G, Preyer M, et al. Influence of Nebivolol and Metoprolol on Inflammatory Mediators in Human Coronary Endothelial or Smooth Muscle Cells: Effects on Neointima Formation After Balloon Denudation in Carotid Arteries of Rats Treated With Nebivolol. Cellular Physiology and Biochemistry. 2007.Supports nebivolol and metoprolol differences in vascular inflammatory mediators.
  3. Le DE, Pascotto M, Leong-Poi H, et al. Anti-Inflammatory and Pro-Angiogenic Effects of Beta Blockers in a Canine Model of Chronic Ischemic Cardiomyopathy: Comparison Between Carvedilol and Metoprolol. Basic Research in Cardiology. 2013.Supports carvedilol versus metoprolol comparison in ischemic cardiomyopathy.
  4. Welt FGP, Batchelor W, Spears JR, et al. Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement. Journal of the American College of Cardiology. 2024.Supports acute MI inflammatory and reperfusion-injury context relevant to beta-blocker discussion.
  5. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-Being in Patients With Heart Failure: The MERIT-HF Trial. JAMA. 2000;283(10):1295-1302.Supports metoprolol succinate heart failure outcome evidence.
  6. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a New Vasodilator and Beta Adrenoceptor Antagonist, Is an Antioxidant and Free Radical Scavenger. Journal of Pharmacology and Experimental Therapeutics. 1992;263(1):92-98.Supports carvedilol’s intrinsic antioxidant activity.
  7. Yue TL, McKenna PJ, Gu JL, et al. Carvedilol Prevents Lipid Peroxidation and Oxidative Injury to Endothelial Cells. Hypertension. 1993;22(6):922-928.Supports carvedilol protection against oxidative endothelial injury.
  8. Yasunari K, Maeda K, Nakamura M, et al. Effects of Carvedilol on Oxidative Stress in Polymorphonuclear and Mononuclear Cells in Patients With Essential Hypertension. American Journal of Medicine. 2004.Supports carvedilol effects on oxidative stress in human inflammatory cells.
  9. Münzel T, Gori T. Nebivolol: The Somewhat-Different Beta-Adrenergic Receptor Blocker. Journal of the American College of Cardiology. 2009.Supports nebivolol’s nitric-oxide-mediated vascular effects.
  10. Sanaee F, Jamali F. Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers. Current Pharmaceutical Design. 2013.Supports nebivolol pharmacology in inflammatory states.
Calcium Channel Blockers4 references
  1. Das R, Burke T, Van Wagoner DR, Plow EF. L-Type Calcium Channel Blockers Exert an Antiinflammatory Effect by Suppressing Expression of Plasminogen Receptors on Macrophages. Circulation Research. 2009.Supports calcium channel blocker effects on macrophage recruitment and inflammatory behavior.
  2. Liu W, Matsumori A. Calcium Channel Blockers and Modulation of Innate Immunity. Current Opinion in Infectious Diseases. 2011.Review supporting immunomodulatory effects of calcium channel blockers.
  3. Halici Z, Suleyman H, Cadirci E. Effects of Calcium Channel Blockers on Hyaluronidase-Induced Capillary Vascular Permeability. Archives of Pharmacal Research. 2008.Supports CCB effects on vascular permeability and inflammation.
  4. Toba H, Nakagawa Y, Miki S, et al. Calcium Channel Blockades Exhibit Anti-Inflammatory and Antioxidative Effects by Augmentation of Endothelial Nitric Oxide Synthase and the Inhibition of Angiotensin Converting Enzyme in the N(g)-Nitro-L-Arginine Methyl Ester-Induced Hypertensive Rat Aorta: Vasoprotective Effects Beyond the Blood Pressure-Lowering Effects of Amlodipine and Manidipine. Hypertension Research. 2005.Supports CCB antioxidant and eNOS effects beyond blood pressure lowering.
Mineralocorticoid Receptor Antagonists4 references
  1. Patel V, Joharapurkar A, Jain M. Role of Mineralocorticoid Receptor Antagonists in Kidney Diseases. Drug Development Research. 2021.Supports MRA anti-inflammatory and renal effects.
  2. Muñoz-Durango N, Vecchiola A, Gonzalez-Gomez LM, et al. Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone. BioMed Research International. 2015.Supports aldosterone and mineralocorticoid receptor effects on inflammation.
  3. Pitt B, Zannad F, Remme WJ, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure. New England Journal of Medicine. 1999.RALES trial; supports spironolactone heart failure outcome evidence.
  4. Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients With Left Ventricular Dysfunction After Myocardial Infarction. New England Journal of Medicine. 2003.EPHESUS trial; supports eplerenone cardiovascular outcome evidence.
Antiplatelet Agents and Aspirin7 references
  1. Thomas MR, Storey RF. Effect of P2Y12 Inhibitors on Inflammation and Immunity. Thrombosis and Haemostasis. 2015.Supports anti-inflammatory and immune effects of P2Y12 inhibitors.
  2. Massaro M, Scoditti E, Carluccio MA, et al. Dipyridamole Decreases Inflammatory Metalloproteinase-9 Expression and Release by Human Monocytes. Thrombosis and Haemostasis. 2013.Supports dipyridamole effects on MMP-9 and inflammatory monocyte signaling.
  3. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012.Guideline support for antiplatelet therapy.
  4. Müller KA, Chatterjee M, Rath D, Geisler T. Platelets, Inflammation and Anti-Inflammatory Effects of Antiplatelet Drugs in ACS and CAD. Thrombosis and Haemostasis. 2015.Supports platelet-inflammation links and anti-inflammatory effects of antiplatelet drugs.
  5. Yin MJ, Yamamoto Y, Gaynor RB. The Anti-Inflammatory Agents Aspirin and Salicylate Inhibit the Activity of IκB Kinase-β. Nature. 1998;396(6706):77-80.Supports aspirin and salicylate inhibition of IKK-β / NF-κB signaling.
  6. Kopp E, Ghosh S. Inhibition of NF-κB by Sodium Salicylate and Aspirin. Science. 1994;265(5174):956-959.Supports aspirin-related NF-κB inhibition independent of classic COX effects.
  7. Weber C, Erl W, Pietsch A, Weber PC. Aspirin Inhibits Nuclear Factor-κB Mobilization and Monocyte Adhesion in Stimulated Human Endothelial Cells. Circulation. 1995;91(7):1914-1917.Supports aspirin effects on NF-κB and monocyte adhesion in endothelial cells.
Colchicine as Cardiovascular Anti-Inflammatory Therapy7 references
  1. Ebrahimi F, Ebrahimi R, Beer M, et al. Colchicine for the Secondary Prevention of Cardiovascular Events.Cochrane Database of Systematic Reviews. 2025.Systematic review supporting colchicine for secondary cardiovascular prevention.
  2. Nelson K, Fuster V, Ridker PM. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACCReview Topic of the Week. Journal of the American College of Cardiology. 2023;82(7):648-660.Supports colchicine mechanisms, COLCOT, and LoDoCo2 evidence.
  3. Zhang FS, He QZ, Qin CH, et al. Therapeutic Potential of Colchicine in Cardiovascular Medicine: A Pharmacological Review. Acta Pharmacologica Sinica. 2022;43(9):2173-2190.Supports colchicine effects on NF-κB, NLRP3, microtubules, and neutrophil biology.
  4. Jannink J, van Zelm AM, Chemlal S, et al. Colchicine in Coronary Artery Disease: ComparativeReview of CLEAR SYNERGY, LoDoCo2 and COLCOT. Current Atherosclerosis Reports. 2026;28(1):11.Supports comparison of colchicine cardiovascular outcome trials.
  5. Silvis MJM, Fiolet ATL, Opstal TSJ, et al. Colchicine Reduces Extracellular Vesicle NLRP3 Inflammasome Protein Levels in Chronic Coronary Disease: A LoDoCo2 Biomarker Substudy. Atherosclerosis. 2021;334:49-56.Supports direct biomarker evidence that colchicine reduces NLRP3 inflammasome protein levels.
  6. Yang M, Lv H, Liu Q, et al. Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis Through Activating AMPK/SIRT1 Pathway. Oxidative Medicine and Cellular Longevity. 2019;2019:9174803.Supports colchicine effects on cholesterol-crystal-induced endothelial inflammation and NLRP3-related pyroptosis.
  7. Spel L, Martinon F. Inflammasomes Contributing to Inflammation in Arthritis. Immunological Reviews. 2020;294(1):48-62.Supports inflammasome biology relevant to colchicine and NLRP3.
Cardiovascular Disease, Residual Inflammatory Risk, and Disease Context5 references
  1. Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement. Journal of the American College of Cardiology. 2025.Core reference for residual inflammatory risk, hsCRP, and inflammation as a cardiovascular treatment target.
  2. Ridker PM. A Test in Context: High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology. 2016.Supports hsCRP as a clinical marker of residual inflammatory risk.
  3. Ridker PM. LDL Cholesterol: Controversies and Future Therapeutic Directions. Lancet. 2014.Supports the relationship between lipid lowering, inflammation, and future cardiovascular therapeutic directions.
  4. Ridker PM. Moving Toward New Statin Guidelines in a Post-JUPITER World: Principles to Consider. Current Atherosclerosis Reports. 2009.Supports interpretation of JUPITER-era statin and inflammation evidence.
  5. Lee SG, Lee SJ, Thuy NVP, et al. Synergistic Protective Effects of a Statin and an Angiotensin Receptor Blocker for Initiation and Progression of Atherosclerosis. PLoS One. 2019.Supports combined statin and ARB anti-atherosclerotic effects.
Cardiovascular Safety and Heart Failure Context8 references
  1. Ford B, Dore M, Bartlett B. Management of Heart Failure: Updated Guidelines From the AHA/ACC. American Family Physician. 2023.Supports guideline-based heart failure treatment context.
  2. Bozkurt B. How to Initiate and Uptitrate Guideline-Directed Medical Therapy in Heart Failure: Practical Stepwise Approach to Optimization of GDMT. JACC: Heart Failure. 2022.Supports practical heart failure medication sequencing.
  3. Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023.Supports loop diuretic comparison in heart failure.
  4. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020.Supports diuretic therapy context in heart failure.
  5. Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. New England Journal of Medicine. 2017.Supports loop diuretic use and heart failure volume-management context.
  6. Buggey J, Mentz RJ, Pitt B, et al. A Reappraisal of Loop Diuretic Choice in Heart Failure Patients. American Heart Journal. 2015.Supports loop diuretic choice discussion.
  7. Díez J, González A, Kovacic JC. Myocardial Interstitial Fibrosis in Nonischemic Heart Disease. Journal of the American College of Cardiology. 2020.Supports cardiac fibrosis context relevant to torsemide and aldosterone pathways.
  8. Cooper LB, Bruce S, Psotka M, et al. Proteomic Differences Among Patients With Heart Failure Taking Furosemide or Torsemide. Clinical Cardiology. 2022.Supports biologic comparison of torsemide and furosemide in heart failure.
Metabolic Medications55 references
Metformin8 references
  1. Kristófi R, Eriksson JW. Metformin as an Anti-Inflammatory Agent: A Short Review. The Journal of Endocrinology. 2021.Supports metformin as an anti-inflammatory agent beyond glucose control.
  2. Postler TS, Peng V, Bhatt DM, Ghosh S. Metformin Selectively Dampens the Acute Inflammatory Response Through an AMPK-Dependent Mechanism. Scientific Reports. 2021.Supports metformin’s AMPK-dependent anti-inflammatory mechanism.
  3. Zhang L, Lu L, Zhong X, et al. Metformin Reduced NLRP3 Inflammasome Activity in Ox-LDL Stimulated Macrophages Through Adenosine Monophosphate Activated Protein Kinase and Protein Phosphatase 2A. European Journal of Pharmacology. 2019.Supports metformin effects on AMPK, protein phosphatase 2A, NF-κB, and NLRP3.
  4. Xian H, Liu Y, Rundberg Nilsson A, et al. Metformin Inhibition of Mitochondrial ATP and DNA Synthesis Abrogates NLRP3 Inflammasome Activation and Pulmonary Inflammation. Immunity. 2021.Supports metformin’s NLRP3 suppression through mitochondrial ATP and DNA synthesis effects.
  5. Tang G, Duan F, Li W, et al. Metformin Inhibited Nod-Like Receptor Protein 3 Inflammasomes Activation and Suppressed Diabetes-Accelerated Atherosclerosis in ApoE Mice. Biomedicine & Pharmacotherapy. 2019.Supports metformin’s NLRP3 and atherosclerosis-related inflammatory effects.
  6. Djebri NC, Zoudji S, Messaoud A, et al. Metformin Inhibits NF-κB p65/RelA-NLRP3 Inflammasome-IL-1β Axis. International Immunopharmacology. 2025.Supports metformin activity across the NF-κB / NLRP3 / IL-1β inflammatory axis.
  7. Scheen AJ, Esser N, Paquot N. Antidiabetic Agents: Potential Anti-Inflammatory Activity Beyond Glucose Control. Diabetes & Metabolism. 2015.Broad review supporting anti-inflammatory effects of metformin and other diabetes drug classes.
  8. Ullah A, Shen B. Immunomodulatory Effects of Anti-Diabetic Therapies: Cytokine and Chemokine Modulation by Metformin, Sodium-Glucose Cotransporter 2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists (2013–2025). European Journal of Medicinal Chemistry. 2025.Supports cytokine and chemokine modulation by metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.
SGLT2 Inhibitors12 references
  1. Shu B, Chen X, Liu Z, et al. Pleiotropic Effects of SGLT2 Inhibitors: A Focus on Macrophage-Mediated Action. Pharmacological Research. 2025.Supports macrophage-mediated anti-inflammatory effects of SGLT2 inhibitors.
  2. Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020.Supports SGLT2 inhibitor cardiorenal mechanisms and anti-inflammatory relevance.
  3. Bendotti G, Montefusco L, Pastore I, et al. The Anti-Inflammatory and Immunological Properties of SGLT-2 Inhibitors. Journal of Endocrinological Investigation. 2023.Supports immune and anti-inflammatory properties of SGLT2 inhibitors.
  4. Schönberger E, Mihaljević V, Steiner K, et al. Immunomodulatory Effects of SGLT2 Inhibitors: Targeting Inflammation and Oxidative Stress in Aging. International Journal of Environmental Research and Public Health. 2023.Supports SGLT2 inhibitor effects on inflammation, oxidative stress, and aging-related biology.
  5. Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular Protection by SGLT2 Inhibitors — Do Anti-Inflammatory Mechanisms Play a Role? Molecular Metabolism. 2022.Supports anti-inflammatory mechanisms as part of SGLT2 cardiovascular protection.
  6. Kim SR, Lee SG, Kim SH, et al. SGLT2 Inhibition Modulates NLRP3 Inflammasome Activity via Ketones and Insulin in Diabetes With Cardiovascular Disease. Nature Communications. 2020.Supports SGLT2-related NLRP3 suppression through ketone and insulin pathways.
  7. Benetti E, Mastrocola R, Vitarelli G, et al. Empagliflozin Protects Against Diet-Induced NLRP3 Inflammasome Activation and Lipid Accumulation. Journal of Pharmacology and Experimental Therapeutics. 2016.Supports empagliflozin effects on NLRP3, lipid accumulation, and metabolic inflammation.
  8. Ke Q, Shi C, Lv Y, et al. SGLT2 Inhibitor Counteracts NLRP3 Inflammasome via Tubular Metabolite Itaconate in Fibrosis Kidney. FASEB Journal. 2022.Supports dapagliflozin/SGLT2 inhibitor effects on renal NLRP3-related inflammation.
  9. Hendawy N, El-Sayed SM, AbdelWahed DM, et al. Empagliflozin Attenuates Pyroptosis by Regulating Thioredoxin-NLRP3 Inflammasome Axis in Atherosclerosis. Journal of Pharmacy and Pharmacology. 2025.Supports empagliflozin effects on the TXNIP/NLRP3 inflammasome axis.
  10. Cliff CL, Shah MU, Ward JK, et al. Timing-Dependent Anti-Inflammatory Effects of Empagliflozin in Monocyte-Derived Macrophages From Post-MI Patients With Type 2 Diabetes. Cardiovascular Diabetology. 2026.Supports empagliflozin effects on macrophage inflammatory priming and activation.
  11. Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin Inhibits Interleukin-1β-Stimulated Cytokine and Chemokine Secretion in Vascular Endothelial Cells by AMP-Activated Protein Kinase-Dependent and -Independent Mechanisms. Scientific Reports. 2018.Supports canagliflozin’s direct endothelial anti-inflammatory effects.
  12. Theofilis P, Sagris M, Oikonomou E, et al. The Impact of SGLT2 Inhibitors on Inflammation: ASystematic Review and Meta-Analysis of Studies in Rodents. International Immunopharmacology. 2022.Supports anti-inflammatory effects of SGLT2 inhibitors across preclinical studies.
GLP-1 Receptor Agonists and Tirzepatide11 references
  1. Sattar N, Linetzky B, Ruotolo G, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology. 2026.Supports tirzepatide reductions in inflammatory and cardiometabolic biomarkers.
  2. Masson W, Lobo M, Nogueira JP, et al. Anti-Inflammatory Effects of Tirzepatide: ASystematic Review and Meta-Analysis. Reviews in Endocrine & Metabolic Disorders. 2026.Supports tirzepatide effects on inflammatory markers.
  3. Wilson JM, Lin Y, Luo MJ, et al. The Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Biomarkers in Patients With Type 2 Diabetes: A Post Hoc Analysis. Diabetes, Obesity & Metabolism. 2022.Supports tirzepatide effects on cardiovascular and inflammatory biomarkers in type 2 diabetes.
  4. Bray JJH, Foster-Davies H, Salem A, et al. Glucagon-Like Peptide-1 Receptor Agonists Improve Biomarkers of Inflammation and Oxidative Stress: ASystematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity & Metabolism. 2021.Supports GLP-1 receptor agonist effects on inflammation and oxidative stress biomarkers.
  5. Alrasheed T, Mostafa MEA, Madkhali MA, Khairy HA. Inflammatory Biomarker Response to GLP-1 Receptor Agonists Versus Other Glucose-Lowering Medications in Patients With Type 2 Diabetes: ASystematic Review and Meta-Analysis. Frontiers in Endocrinology. 2025.Supports GLP-1 receptor agonist effects on inflammatory biomarkers compared with other diabetes medications.
  6. Ren Y, Chen Y, Zheng W, et al. The Effect of GLP-1 Receptor Agonists on Circulating Inflammatory Markers in Type 2 Diabetes:Systematic Review and Meta-Analysis. Diabetes, Obesity & Metabolism. 2025.Supports GLP-1 receptor agonist reductions in circulating inflammatory markers.
  7. Ngabea MA, Dimeji IY. GLP-1 Receptor Agonists and Inflammatory Pathway Modulation: Dual Targeting of Metabolic and Immune Dysfunction. Biochemical and Biophysical Research Communications. 2025.Supports GLP-1 receptor agonist modulation of NF-κB, JNK, and NLRP3 pathways.
  8. Dandona P, Ghanim H, Chaudhuri A. Incretins: Beyond Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2018.Supports broader anti-inflammatory and metabolic effects of incretin therapies.
  9. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis With Liver Fibrosis. New England Journal of Medicine. 2024.Supports tirzepatide benefit in MASH/MASLD and liver-related metabolic inflammation.
  10. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025.Supports MASLD/MASH screening and metabolic intervention context in diabetes.
  11. Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of Tirzepatide Versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in People With Type 2 Diabetes (SURPASS-3 MRI): A Substudy of the Randomised, Open-Label, Parallel-Group, Phase 3 SURPASS-3 Trial. Lancet Diabetes & Endocrinology. 2022.Supports tirzepatide effects on liver fat and abdominal adipose tissue.
DPP-4 Inhibitors4 references
  1. Xie D, Wang Q, Huang W, Zhao L. Dipeptidyl-Peptidase-4 Inhibitors Have Anti-Inflammatory Effects in Patients With Type 2 Diabetes. European Journal of Clinical Pharmacology. 2023.Systematic review supporting anti-inflammatory effects of DPP-4 inhibitors.
  2. Makdissi A, Ghanim H, Vora M, et al. Sitagliptin Exerts an Antiinflammatory Action. Journal of Clinical Endocrinology and Metabolism. 2012.Supports sitagliptin’s anti-inflammatory activity and rapid NF-κB-related effects.
  3. Zhuge F, Ni Y, Nagashimada M, et al. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization. Diabetes. 2016.Supports linagliptin effects on macrophage polarization and obesity-related inflammation.
  4. Dandona P, Ghanim H, Chaudhuri A. Incretins: Beyond Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2018.Also supports DPP-4 and incretin-related anti-inflammatory biology.
Thiazolidinediones / Pioglitazone5 references
  1. Scheen AJ, Esser N, Paquot N. Antidiabetic Agents: Potential Anti-Inflammatory Activity Beyond Glucose Control. Diabetes & Metabolism. 2015.Broad review supporting TZD and other antidiabetic anti-inflammatory effects.
  2. Orasanu G, Ziouzenkova O, Devchand PR, et al. The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α-Dependent Manner in Vitro and in Vivo in Mice. Journal of the American College of Cardiology. 2008.Supports pioglitazone repression of inflammation through PPAR-related pathways.
  3. Hanefeld M, Marx N, Pfützner A, et al. Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study. Journal of the American College of Cardiology. 2007.Supports pioglitazone effects on hsCRP and additive anti-inflammatory effects with statin therapy.
  4. Vijay SK, Mishra M, Kumar H, Tripathi K. Effect of Pioglitazone and Rosiglitazone on Mediators of Endothelial Dysfunction, Markers of Angiogenesis and Inflammatory Cytokines in Type 2 Diabetes. Acta Diabetologica. 2009.Supports comparison of pioglitazone and rosiglitazone on inflammatory cytokines and endothelial dysfunction.
  5. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone After Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2016.IRIS trial; supports vascular outcome evidence for pioglitazone in insulin-resistant patients.
Alpha-Glucosidase Inhibitors / Acarbose6 references
  1. Mo D, Liu S, Ma H, et al. Effects of Acarbose and Metformin on the Inflammatory State in Newly Diagnosed Type 2 Diabetes Patients: A One-Year Randomized Clinical Study. Drug Design, Development and Therapy. 2019.Supports acarbose effects on inflammatory markers compared with metformin.
  2. Bethel MA, Xu W, Theodorakis MJ. Pharmacological Interventions for Preventing or Delaying Onset of Type 2 Diabetes Mellitus. Diabetes, Obesity & Metabolism. 2015.Supports acarbose and other metabolic interventions in diabetes prevention context.
  3. Chen HH, Chen DY, Chao YH, et al. Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-Induced Arthritis in Mice. Scientific Reports. 2015.Supports acarbose association with lower rheumatoid arthritis risk and experimental inflammatory arthritis effects.
  4. Derosa G, Maffioli P, Ferrari I, et al. Acarbose Actions on Insulin Resistance and Inflammatory Parameters During an Oral Fat Load. European Journal of Pharmacology. 2011.Supports acarbose effects on insulin resistance and postprandial inflammatory parameters.
  5. Zhao B, Wu F, Han X, et al. Protective Effects of Acarbose Against Insulitis in Multiple Low-Dose Streptozotocin-Induced Diabetic Mice. Life Sciences. 2020.Supports acarbose effects on inflammatory pancreatic injury in preclinical diabetes models.
  6. Mao PC, Chung MI, Hung YM, Chen HM, Chen CL. Acarbose Might Be Associated With Reduced Risk of Gastric Cancer in Patients With Diabetes Mellitus: A Nationwide Population-Based Cohort Study. Pharmacoepidemiology and Drug Safety. 2024.Supports acarbose as a metabolic drug with possible broader disease associations.
Sulfonylureas and Insulin as Comparators3 references
  1. Lowes DJ, Hevener KE, Peters BM. Second-Generation Antidiabetic Sulfonylureas Inhibit Candida Albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome. Antimicrobial Agents and Chemotherapy. 2020.Supports preclinical NLRP3-related effects of second-generation sulfonylureas.
  2. Hill JR, Coll RC, Sue N, et al. Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors. ChemMedChem. 2017.Supports sulfonylurea effects on NLRP3 in mechanistic models.
  3. Scheen AJ, Esser N, Paquot N. Antidiabetic Agents: Potential Anti-Inflammatory Activity Beyond Glucose Control. Diabetes & Metabolism. 2015.Supports the conclusion that sulfonylureas have weaker clinical anti-inflammatory translation compared with metformin, TZDs, GLP-1 agents, and SGLT2 inhibitors.
Diabetes / Metabolic Disease Guideline and Disease Context6 references
  1. American Diabetes Association / KDIGO Consensus Report. Diabetes Management in Chronic Kidney Disease. Diabetes Care. 2022.Supports metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and organ-protection framework in diabetes with CKD.
  2. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2026.Supports current diabetes treatment framework and organ-protective drug selection.
  3. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. Diabetes Care. 2025.Supports diabetes, metabolic liver disease, and early intervention framework.
  4. La Grotta R, de Candia P, Olivieri F, et al. Anti-Inflammatory Effect of SGLT-2 Inhibitors via Uric Acid and Insulin. Cellular and Molecular Life Sciences. 2022.Supports SGLT2 inhibitor anti-inflammatory effects through uric acid and insulin pathways.
  5. Dandona P, Ghanim H, Chaudhuri A. Incretins: Beyond Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2018.Supports incretin biology beyond glucose lowering.
  6. Ullah A, Shen B. Immunomodulatory Effects of Anti-Diabetic Therapies: Cytokine and Chemokine Modulation by Metformin, Sodium-Glucose Cotransporter 2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists (2013–2025). European Journal of Medicinal Chemistry. 2025.Broad metabolic medication reference supporting the shield framework across metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.
Gout, Uric Acid, and Crystal Inflammation40 references
Gout / Hyperuricemia Disease Context4 references
  1. Spel L, Martinon F. Inflammasomes Contributing to Inflammation in Arthritis. Immunological Reviews. 2020;294(1):48-62.Supports inflammasome biology in arthritis and crystal-driven inflammation.
  2. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-Associated Uric Acid Crystals Activate the NALP3 Inflammasome. Nature. 2006;440(7081):237-241.Core mechanistic reference showing that uric acid crystals activate the NLRP3 inflammasome.
  3. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-1855.Broad clinical review supporting gout as a systemic urate and inflammatory disease.
  4. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of RheumatologyGuideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744-760.Guideline support for allopurinol as first-line urate-lowering therapy, uric acid targets, colchicine prophylaxis, and flare management.
Xanthine Oxidase / Oxidative Stress5 references
  1. Okafor ON, Farrington K, Gorog DA. Allopurinol as a Therapeutic Option in Cardiovascular Disease. Pharmacology & Therapeutics. 2017;172:139-150.Supports allopurinol as an xanthine oxidase inhibitor with oxidative stress and cardiovascular relevance.
  2. Zhang YS, Lu LQ, Jiang YQ, et al. Allopurinol Attenuates Oxidative Injury in Rat Hearts via Suppressing the Xanthine Oxidase / Vascular Peroxidase 1 Pathway. European Journal of Pharmacology. 2021;908:174368.Supports allopurinol effects on xanthine oxidase-linked oxidative injury.
  3. Liu N, Xu H, Sun Q, et al. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase Inhibitors. Oxidative Medicine and Cellular Longevity. 2020;2020:1470380.Supports the connection among hyperuricemia, oxidative stress, and xanthine oxidoreductase inhibition.
  4. Vickneson K, George J. Xanthine Oxidoreductase Inhibitors. Handbook of Experimental Pharmacology. 2020;264:205-228.Supports xanthine oxidoreductase inhibitor pharmacology and oxidative stress reduction.
  5. Weisman A, Tomlinson GA, Lipscombe LL, et al. Association Between Allopurinol and Cardiovascular Outcomes and All-Cause Mortality in Diabetes. Diabetes, Obesity & Metabolism. 2019;21(6):1322-1329.Supports observational cardiovascular outcome context for allopurinol in diabetes.
Allopurinol6 references
  1. Schlesinger N, Brunetti L. Beyond Urate Lowering: Analgesic and Anti-Inflammatory Properties of Allopurinol. Seminars in Arthritis and Rheumatism. 2020;50(3):444-450.Supports allopurinol anti-inflammatory properties beyond urate lowering.
  2. Okafor ON, Farrington K, Gorog DA. Allopurinol as a Therapeutic Option in Cardiovascular Disease. Pharmacology & Therapeutics. 2017;172:139-150.Supports allopurinol’s cardiovascular and oxidative stress rationale.
  3. Liu N, Xu H, Sun Q, et al. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase Inhibitors. Oxidative Medicine and Cellular Longevity. 2020;2020:1470380.Supports allopurinol’s role in reducing oxidative stress through xanthine oxidase inhibition.
  4. Zhang YS, Lu LQ, Jiang YQ, et al. Allopurinol Attenuates Oxidative Injury in Rat Hearts via Suppressing the Xanthine Oxidase / Vascular Peroxidase 1 Pathway. European Journal of Pharmacology. 2021;908:174368.Supports mechanistic oxidative stress effects relevant to the oxidative stress shield.
  5. Stamp LK, Day RO, Yun J. Allopurinol Hypersensitivity: Investigating the Cause and Minimizing the Risk. Nature Reviews Rheumatology. 2016;12(4):235-242.Supports HLA-B*58:01 and allopurinol hypersensitivity safety discussion.
  6. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing. Clinical Pharmacology & Therapeutics. 2013;93(2):153-158.Supports HLA-B*58:01 testing and allopurinol safety guidance.
Febuxostat6 references
  1. Hu M, Zhou Y, Zhang Y, Pan F, Liu M. Febuxostat Alleviates Gout-Associated Hyperuricemia and Inflammation by Downregulating IL1A to Modulate TLR2 / TLR4 / NF-κB Signaling Pathway. International Immunopharmacology. 2025.Supports febuxostat effects on TLR/NF-κB inflammatory signaling.
  2. Suzuki Y, Deguchi M, Furuya A, Kato S, Ohta S. Febuxostat Attenuates the Induction of Vascular Cell Adhesion Protein 1 by TNF-α in Human Umbilical Vein Endothelial Cells. Pharmacology. 2020.Supports febuxostat effects on endothelial inflammatory activation.
  3. Khan SI, Malhotra RK, Rani N, et al. Febuxostat Modulates MAPK / NF-κBp65 / TNF-α Signaling in Cardiac Ischemia-Reperfusion Injury. Oxidative Medicine and Cellular Longevity. 2017.Supports febuxostat effects on NF-κB, TNF-α, and oxidative injury pathways.
  4. Amirshahrokhi K. Febuxostat Attenuates Ulcerative Colitis by the Inhibition of NF-κB, Proinflammatory Cytokines, and Oxidative Stress in Mice. International Immunopharmacology. 2019.Supports febuxostat NF-κB and oxidative stress effects in inflammatory disease models.
  5. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout. New England Journal of Medicine. 2018;378(13):1200-1210.CARES trial; supports febuxostat cardiovascular safety warning.
  6. Mackenzie IS, Ford I, Nuki G, et al. Long-Term Cardiovascular Safety of Febuxostat Compared With Allopurinol in Patients With Gout:FAST Trial. Lancet. 2020;396(10264):1745-1757.FAST trial; provides cardiovascular safety comparison between febuxostat and allopurinol.
Colchicine in Gout and NLRP3 Suppression6 references
  1. Nelson K, Fuster V, Ridker PM. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACCReview Topic of the Week. Journal of the American College of Cardiology. 2023;82(7):648-660.Supports colchicine’s NLRP3, microtubule, neutrophil, and cardiovascular anti-inflammatory mechanisms.
  2. Zhang FS, He QZ, Qin CH, et al. Therapeutic Potential of Colchicine in Cardiovascular Medicine: A Pharmacological Review. Acta Pharmacologica Sinica. 2022;43(9):2173-2190.Supports colchicine effects on NLRP3, NF-κB, microtubules, and inflammatory signaling.
  3. Silvis MJM, Fiolet ATL, Opstal TSJ, et al. Colchicine Reduces Extracellular Vesicle NLRP3 Inflammasome Protein Levels in Chronic Coronary Disease: A LoDoCo2 Biomarker Substudy. Atherosclerosis. 2021;334:49-56.Supports direct biomarker evidence of colchicine reducing NLRP3 inflammasome protein levels.
  4. Yang M, Lv H, Liu Q, et al. Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis Through Activating AMPK/SIRT1 Pathway. Oxidative Medicine and Cellular Longevity. 2019;2019:9174803.Supports colchicine effects on cholesterol-crystal inflammatory injury and NLRP3-related pyroptosis.
  5. Leung YY, Yao Hui LL, Kraus VB. Colchicine — Update on Mechanisms of Action and Therapeutic Uses. Seminars in Arthritis and Rheumatism. 2015;45(3):341-350.Supports colchicine mechanisms in gout and other inflammatory diseases.
  6. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: Old and New. American Journal of Medicine. 2015;128(5):461-470.Supports colchicine’s traditional gout role and newer anti-inflammatory applications.
Losartan and Uric Acid4 references
  1. Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Comparative Effects of Losartan and Irbesartan on Serum Uric Acid in Hypertensive Patients With Hyperuricemia and Gout. Journal of Hypertension. 2001;19(10):1855-1860.Supports losartan’s uricosuric effect compared with another ARB.
  2. Shahinfar S, Simpson RL, Carides AD, et al. Safety of Losartan in Hypertensive Patients With Thiazide-Induced Hyperuricemia. Kidney International. 1999;56(5):1879-1885.Supports losartan lowering uric acid in thiazide-related hyperuricemia.
  3. Krämer C, Sunkomat J, Witte J, et al. Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179. Circulation Research. 2002;90(7):770-776.Supports losartan anti-inflammatory properties beyond blood pressure control.
  4. Fortuño A, Bidegain J, Robador PA, et al. Losartan Metabolite EXP3179 Blocks NADPH Oxidase-Mediated Superoxide Production by Inhibiting Protein Kinase C: Potential Clinical Implications in Hypertension. Hypertension. 2009.Supports losartan metabolite effects on oxidative stress.
SGLT2 Inhibitors and Uric Acid3 references
  1. La Grotta R, de Candia P, Olivieri F, et al. Anti-Inflammatory Effect of SGLT-2 Inhibitors via Uric Acid and Insulin. Cellular and Molecular Life Sciences. 2022.Supports the concept that SGLT2 inhibitors reduce inflammatory pressure partly through uric acid and insulin effects.
  2. Zhao Y, Xu L, Tian D, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Uric Acid in Patients With Type 2 Diabetes Mellitus: ASystematic Review and Meta-Analysis. Diabetes, Obesity & Metabolism. 2018;20(2):458-462.Supports SGLT2 inhibitor uric-acid lowering as a class effect.
  3. Chino Y, Samukawa Y, Sakai S, et al. SGLT2 Inhibitor Lowers Serum Uric Acid Through Alteration of Uric Acid Transport Activity in Renal Tubule. Diabetes, Obesity & Metabolism. 2014;16(5):435-438.Supports a renal tubular mechanism for SGLT2 inhibitor uric acid lowering.
NSAIDs / Prednisone as Gout-Flare Context3 references
  1. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of RheumatologyGuideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744-760.Supports NSAIDs, colchicine, and glucocorticoids as acute flare options and provides guideline context.
  2. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Anti-Inflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care & Research. 2012;64(10):1447-1461.Older but useful guideline support for flare treatment and prophylaxis.
  3. Terkeltaub RA. Clinical Practice: Gout. New England Journal of Medicine. 2003;349(17):1647-1655.Classic clinical review supporting the management of gout and flare therapy.
Safety and Drug-Interaction References Relevant to Gout Medications3 references
  1. Terkeltaub RA, Furst DE, Bennett K, et al. High Versus Low Dosing of Oral Colchicine for Early Acute Gout Flare: Twenty-Four-Hour Outcome of the First Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Colchicine Study. Arthritis & Rheumatism. 2010;62(4):1060-1068.Supports low-dose colchicine approach for acute gout flare.
  2. Stamp LK, Chapman PT. Gout and Its Comorbidities: Implications for Therapy. Rheumatology. 2013;52(1):34-44.Supports gout comorbidity considerations, including kidney disease and cardiovascular risk.
  3. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039-2052.Supports gout pathophysiology, treatment, and systemic comorbidity context.
Pain, Inflammation, and Connective-Tissue Medications58 references
NSAIDs and COX-Independent Anti-Inflammatory Effects9 references
  1. Dinarello CA. Anti-Inflammatory Agents: Present and Future. Cell. 2010.Broad reference on anti-inflammatory drug classes and cytokine-directed inflammatory biology.
  2. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-Independent Actions of Cyclooxygenase Inhibitors. FASEB Journal. 2001.Supports the concept that some NSAID effects occur beyond COX inhibition, including NF-κB and AP-1-related mechanisms.
  3. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal Anti-Inflammatory Agents Differ in Their Ability to Suppress NF-κB Activation, Inhibition of Expression of Cyclooxygenase-2 and Cyclin D1, and Abrogation of Tumor Cell Proliferation. Oncogene. 2004.Supports within-class differences among NSAIDs in NF-κB suppression.
  4. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase-2 Inhibitor Celecoxib Abrogates TNF-Induced NF-κB Activation Through Inhibition of Activation of IκBα Kinase and Akt in Human Non-Small Cell Lung Carcinoma: Correlation With Suppression of COX-2 Synthesis. Journal of Immunology. 2004.Supports celecoxib suppression of TNF-induced NF-κB activation.
  5. Al-Rashed F, Calay D, Lang M, et al. Celecoxib Exerts Protective Effects in the Vascular Endothelium via COX-2-Independent Activation of AMPK-CREB-Nrf2 Signalling. Scientific Reports. 2018.Supports celecoxib effects on AMPK, CREB, Nrf2, and oxidative stress pathways independent of COX-2 inhibition.
  6. Funakoshi-Tago M, Shimizu T, Tago K, et al. Celecoxib Potently Inhibits TNFα-Induced Nuclear Translocation and Activation of NF-κB. Biochemical Pharmacology. 2008.Supports celecoxib as a potent NF-κB inhibitor.
  7. Weber C, Erl W, Pietsch A, Weber PC. Aspirin Inhibits Nuclear Factor-κB Mobilization and Monocyte Adhesion in Stimulated Human Endothelial Cells. Circulation. 1995;91(7):1914-1917.Supports aspirin-related NF-κB inhibition and reduced endothelial monocyte adhesion.
  8. Yin MJ, Yamamoto Y, Gaynor RB. The Anti-Inflammatory Agents Aspirin and Salicylate Inhibit the Activity of IκB Kinase-β. Nature. 1998;396(6706):77-80.Supports aspirin and salicylate inhibition of IKK-β, a key upstream regulator of NF-κB.
  9. Kopp E, Ghosh S. Inhibition of NF-κB by Sodium Salicylate and Aspirin. Science. 1994;265(5174):956-959.Supports aspirin-related NF-κB inhibition independent of classic COX effects.
NSAID Safety and Use Limits in Older Adults5 references
  1. FitzGerald GA. Coxibs and Cardiovascular Disease. New England Journal of Medicine. 2004;351(17):1709-1711.Supports cardiovascular safety concerns around selective COX-2 inhibition.
  2. Grosser T, Fries S, FitzGerald GA. Biological Basis for the Cardiovascular Consequences of COX-2 Inhibition: Therapeutic Challenges and Opportunities. Journal of Clinical Investigation. 2006;116(1):4-15.Supports the biologic basis for cardiovascular risk with COX-2 inhibition.
  3. Bally M, Dendukuri N, Rich B, et al. Risk of Acute Myocardial Infarction With NSAIDs in Real World Use: Bayesian Meta-Analysis of Individual Patient Data. BMJ. 2017;357:j1909.Supports NSAID cardiovascular risk discussion.
  4. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent Use of Diuretics, Angiotensin Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers With NSAIDs and Risk of Acute Kidney Injury: Nested Case-Control Study. BMJ. 2013;346:e8525.Supports the “triple whammy” kidney-risk warning: NSAID plus ACE inhibitor or ARB plus diuretic.
  5. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use inOlder Adults. Journal of the American Geriatrics Society. 2023.Supports caution with NSAIDs and other high-risk medications in older adults.
Hydroxychloroquine8 references
  1. Richard SA, Kampo S, Hechavarria ME, et al. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. Journal of Immunology Research. 2020.Supports broad immunomodulatory and anti-inflammatory properties of hydroxychloroquine.
  2. Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in Rheumatic Autoimmune Disorders and Beyond. EMBO Molecular Medicine. 2020.Supports hydroxychloroquine mechanisms in autoimmune disease and beyond.
  3. Hu C, Lu L, Wan JP, Wen C. The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases. Current Medicinal Chemistry. 2017.Supports hydroxychloroquine pharmacologic mechanisms in rheumatic disease.
  4. Bahadoram M, Keikhaei B, Saeedi-Boroujeni A, Mahmoudian-Sani MR. Chloroquine/Hydroxychloroquine: An Inflammasome Inhibitor in Severe COVID-19? Naunyn-Schmiedeberg's Archives of Pharmacology. 2021.Supports hydroxychloroquine as an inflammasome-related inhibitor.
  5. Fujita Y, Matsuoka N, Temmoku J, et al. Hydroxychloroquine Inhibits IL-1β Production From Amyloid-Stimulated Human Neutrophils. Arthritis Research & Therapy. 2019.Supports hydroxychloroquine reduction of IL-1β production.
  6. Tang TT, Lv LL, Pan MM, et al. Hydroxychloroquine Attenuates Renal Ischemia/Reperfusion Injury by Inhibiting Cathepsin-Mediated NLRP3 Inflammasome Activation. Cell Death & Disease. 2018.Supports hydroxychloroquine inhibition of cathepsin-mediated NLRP3 activation.
  7. Eugenia Schroeder M, Russo S, Costa C, et al. Pro-Inflammatory Ca-Activated K Channels Are Inhibited by Hydroxychloroquine. Scientific Reports. 2017.Supports hydroxychloroquine effects on K-channel-mediated inflammatory activation.
  8. Chen X, Wang N, Zhu Y, et al. The Antimalarial Chloroquine Suppresses LPS-Induced NLRP3 Inflammasome Activation and Confers Protection Against Murine Endotoxic Shock. Mediators of Inflammation. 2016.Supports chloroquine/hydroxychloroquine-related NLRP3 suppression.
Sulfasalazine and Aminosalicylates6 references
  1. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: A Potent and Specific Inhibitor of Nuclear Factor Kappa B. Journal of Clinical Investigation. 1998.Supports sulfasalazine as a potent NF-κB inhibitor.
  2. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-κB Activity by Sulfasalazine Is Mediated by Direct Inhibition of IκB Kinases Alpha and Beta. Gastroenterology. 2000.Supports direct IKK inhibition by sulfasalazine.
  3. Liptay S, Bachem M, Häcker G, et al. Inhibition of Nuclear Factor Kappa B and Induction of Apoptosis in T-Lymphocytes by Sulfasalazine. British Journal of Pharmacology. 1999.Supports sulfasalazine effects on NF-κB and activated T lymphocytes.
  4. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine Inhibits Activation of Transcription Factor NF-κB in Inflamed Mucosa of Patients With Ulcerative Colitis. American Journal of Gastroenterology. 2000.Supports mesalamine effects on NF-κB in ulcerative colitis mucosa.
  5. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal Anti-Inflammatory Effect of 5-Aminosalicylic Acid Is Dependent on Peroxisome Proliferator-Activated Receptor-γ. Journal of Experimental Medicine. 2005.Supports 5-ASA / mesalamine effects through PPARγ.
  6. Greenfield SM, Punchard NA, Teare JP, Thompson RP.Review Article: The Mode of Action of the Aminosalicylates in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 1993.Broad review supporting aminosalicylate anti-inflammatory mechanisms.
Methotrexate and Conventional DMARD Context4 references
  1. Cronstein BN. Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis. Pharmacological Reviews. 2005.Supports low-dose methotrexate anti-inflammatory mechanisms, including adenosine-mediated effects.
  2. Chan ESL, Cronstein BN. Methotrexate — How Does It Really Work? Nature Reviews Rheumatology. 2010.Supports methotrexate mechanisms in inflammatory disease.
  3. Wessels JAM, Huizinga TWJ, Guchelaar HJ. Recent Insights in the Pharmacological Actions of Methotrexate in the Treatment of Rheumatoid Arthritis. Rheumatology. 2008.Supports methotrexate mechanisms and clinical use in rheumatoid arthritis.
  4. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of RheumatologyGuideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology. 2016.Guideline support for methotrexate and conventional DMARD use in rheumatoid arthritis.
Doxycycline and Sub-Antimicrobial Tetracycline Therapy8 references
  1. Gu Y, Lee HM, Sorsa T, et al. Non-Antibacterial Tetracyclines Modulate Mediators of Periodontitis and Atherosclerotic Cardiovascular Disease: A Mechanistic Link Between Local and Systemic Inflammation. Pharmacological Research. 2011;64(6):573-579.Supports non-antibacterial tetracycline effects on inflammation, MMPs, periodontitis, and vascular disease.
  2. Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study. Mediators of Inflammation. 2015;2015:329418.Supports anti-inflammatory properties of doxycycline at different doses.
  3. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms. Advances in Dental Research. 1998;12(2):12-26.Supports tetracycline inhibition of connective-tissue breakdown and MMPs.
  4. Caton JG, Ciancio SG, Blieden TM, et al. Treatment With Subantimicrobial Dose Doxycycline Improves the Efficacy of Scaling and Root Planing in Patients With Adult Periodontitis. Journal of Periodontology. 2000;71(4):521-532.Supports sub-antimicrobial doxycycline in periodontal disease and host modulation.
  5. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial Dose Doxycycline as Adjunctive Treatment for Periodontitis: A Review. Journal of Clinical Periodontology. 2004;31(9):697-707.Review supporting sub-antimicrobial doxycycline as host-modulation therapy.
  6. Walker C, Preshaw PM, Novak J, Hefti AF, Bradshaw M, Powala C. Long-Term Treatment With Sub-Antimicrobial Dose Doxycycline Has No Antibacterial Effect on Intestinal Flora. Journal of Clinical Periodontology. 2005;32(11):1163-1169.Supports long-term sub-antimicrobial doxycycline safety regarding gut flora and resistance.
  7. Payne JB, Stoner JA, Nummikoski PV, et al. Subantimicrobial Dose Doxycycline Effects on Alveolar Bone Loss in Postmenopausal Women. Journal of Clinical Periodontology. 2007;34(9):776-787.Supports long-term low-dose doxycycline effects in periodontal/bone context.
  8. Brown DL, Desai KK, Vakili BA, et al. Clinical and Biochemical Results of the Metalloproteinase Inhibition With Subantimicrobial Doses of Doxycycline to Prevent Acute Coronary Syndromes Pilot Trial. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24(4):733-738.Supports sub-antimicrobial doxycycline effects on MMPs and inflammatory biomarkers in acute coronary syndrome context.
Minocycline and Tetracycline Within-Class Comparison9 references
  1. Möller T, Bard F, Bhattacharya A, et al. Critical Data-Based Re-Evaluation of Minocycline as a Putative Specific Microglia Inhibitor. Glia. 2016;64(10):1788-1794.Supports careful interpretation of minocycline as a microglial/CNS anti-inflammatory drug.
  2. Garrido-Mesa J, Rodríguez-Nogales A, Algieri F, et al. Immunomodulatory Tetracyclines Shape the Intestinal Inflammatory Response Inducing Mucosal Healing and Resolution. British Journal of Pharmacology. 2018.Supports immunomodulatory effects of tetracyclines in inflammatory tissue.
  3. Bastos LF, Merlo LA, Rocha LT, Coelho MM. Characterization of the Antinociceptive and Anti-Inflammatory Activities of Doxycycline and Minocycline in Different Experimental Models. European Journal of Pharmacology. 2007.Supports direct comparison of doxycycline and minocycline anti-inflammatory activity.
  4. Garrido-Mesa J, Algieri F, Rodríguez-Nogales A, et al. Immunomodulatory Tetracyclines Ameliorate DNBS-Colitis: Impact on microRNA Expression and Microbiota Composition. Biochemical Pharmacology. 2018.Supports tetracyclines, microbiota, and inflammatory gene expression effects.
  5. Lu Y, Yang Y, Chen W, et al. Minocycline, but Not Doxycycline, Attenuates NMDA-Induced Intracellular Calcium and Excitotoxicity. NeuroReport. 2021.Supports minocycline versus doxycycline CNS/excitotoxicity comparison.
  6. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines Inhibit Microglial Activation and Are Neuroprotective in Global Brain Ischemia. Proceedings of the National Academy of Sciences USA. 1998.Supports tetracycline neuroprotective and microglial anti-inflammatory effects.
  7. Chung CL, Tsai HP, Huang YH, et al. Attenuation in Proinflammatory Factors and Reduction in Neuronal Cell Apoptosis and Cerebral Vasospasm by Minocycline During Early Phase After Subarachnoid Hemorrhage in the Rat. BioMed Research International. 2021.Supports minocycline effects on neuroinflammation and neuronal injury.
  8. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline Inhibits Poly(ADP-Ribose) Polymerase-1 at Nanomolar Concentrations. Proceedings of the National Academy of Sciences USA. 2006.Supports minocycline PARP-1 inhibition as a CNS-relevant mechanism.
  9. Yong VW, Wells J, Giuliani F, et al. The Promise of Minocycline in Neurology. Lancet Neurology. 2004.Review supporting minocycline’s neurologic anti-inflammatory potential.
Osteoarthritis, Joint Inflammation, and Musculoskeletal Context6 references
  1. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology / Arthritis FoundationGuideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. 2020;72(2):149-162.Guideline support for exercise, topical NSAIDs, oral NSAIDs, steroid injections, and duloxetine in osteoarthritis.
  2. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI Guidelines for the Non-Surgical Management of Knee, Hip, and Polyarticular Osteoarthritis. Osteoarthritis and Cartilage. 2019;27(11):1578-1589.Guideline support for non-surgical osteoarthritis management.
  3. Loeser RF, Collins JA, Diekman BO. Ageing and the Pathogenesis of Osteoarthritis. Nature Reviews Rheumatology. 2016;12(7):412-420.Supports aging, low-grade inflammation, and osteoarthritis biology.
  4. Robinson WH, Lepus CM, Wang Q, et al. Low-Grade Inflammation as a Key Mediator of the Pathogenesis of Osteoarthritis. Nature Reviews Rheumatology. 2016;12(10):580-592.Supports osteoarthritis as a low-grade inflammatory disease.
  5. Scanzello CR. Role of Low-Grade Inflammation in Osteoarthritis. Current Opinion in Rheumatology. 2017;29(1):79-85.Supports synovial and low-grade inflammatory mechanisms in osteoarthritis.
  6. McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-Articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017;317(19):1967-1975.Supports caution about repeated intra-articular steroid injections in osteoarthritis.
Duloxetine and Chronic Musculoskeletal Pain3 references
  1. Chappell AS, Desaiah D, Liu-Seifert H, et al. A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee. Pain Practice. 2011;11(1):33-41.Supports duloxetine efficacy in chronic osteoarthritis knee pain.
  2. Wang G, Bi L, Li X, et al. Efficacy and Safety of Duloxetine in Osteoarthritis or Chronic Low Back Pain: ASystematic Review and Meta-Analysis. Osteoarthritis and Cartilage. 2015;23(11):1822-1833.Supports duloxetine use in osteoarthritis and chronic musculoskeletal pain.
  3. Tynan RJ, Weidenhofer J, Hinwood M, et al. A Comparative Examination of the Anti-Inflammatory Effects of SSRI and SNRI Antidepressants on LPS-Stimulated Microglia. Brain, Behavior, and Immunity. 2012.Supports SNRI and SSRI effects on microglial inflammatory signaling, including duloxetine/venlafaxine context.
Pulmonary and Antimicrobial Immunomodulators51 references
COPD, Chronic Airway Disease, and Pulmonary Inflammation4 references
  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD. GOLD Report.Guideline support for COPD therapy, inhaled bronchodilators, inhaled corticosteroids in selected patients, roflumilast, and macrolide use in frequent exacerbators.
  2. Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD Exacerbations: A European Respiratory Society / American Thoracic Society Guideline. European Respiratory Journal. 2017.Guideline support for prevention of COPD exacerbations, including macrolide therapy in selected patients.
  3. Barnes PJ. Inflammatory Mechanisms in Patients With Chronic Obstructive Pulmonary Disease. Journal of Allergy and Clinical Immunology. 2016.Supports COPD as a chronic inflammatory airway disease involving neutrophils, macrophages, NF-κB activation, oxidative stress, and inflammatory cytokines.
  4. Barnes PJ. Cellular and Molecular Mechanisms of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine. 2014.Supports COPD inflammatory biology, oxidative stress, airway remodeling, and tissue destruction.
Macrolides and Azithromycin9 references
  1. Albert RK, Connett J, Bailey WC, et al. Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine. 2011;365(8):689-698.Landmark randomized trial supporting azithromycin for COPD exacerbation prevention; showed reduced exacerbation frequency and longer time to first exacerbation.
  2. Janjua S, Mathioudakis AG, Fortescue R, et al. Prophylactic Antibiotics for Adults With Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.Cochrane Database of Systematic Reviews. 2021.Supports macrolides as the leading prophylactic antibiotic class for COPD exacerbation prevention, with tetracyclines ranking below macrolides.
  3. Kricker JA, Page CP, Gardarsson FR, et al. Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacological Reviews. 2021.Supports non-antimicrobial immunomodulatory effects of macrolides, including airway anti-inflammatory mechanisms.
  4. Steel HC, Theron AJ, Cockeran R, Anderson R, Feldman C. Pathogen- and Host-Directed Anti-Inflammatory Activities of Macrolide Antibiotics. Mediators of Inflammation. 2012.Supports macrolide effects on neutrophils, macrophages, cytokines, and airway inflammation.
  5. Gualdoni GA, Lingscheid T, Schmetterer KG, et al. Azithromycin Inhibits IL-1 Secretion and Non-Canonical Inflammasome Activation. Scientific Reports. 2015.Supports azithromycin effects on IL-1 secretion and inflammasome-related inflammatory pathways.
  6. Taguchi K, Chuang VTG, Ogino H, et al. Direct Comparison of Anti-Inflammatory Effects of 14-, 15-, and 16-Membered Macrolide Antibiotics in Experimental Inflammation Model Induced by Carrageenan in Rats. Pharmazie. 2024.Supports within-class differences among macrolides and the importance of macrolide ring structure for anti-inflammatory activity.
  7. Crosbie PAJ, Woodhead MA. Long-Term Macrolide Therapy in Chronic Inflammatory Airway Diseases. European Respiratory Journal. 2009.Supports macrolide use as immunomodulatory therapy in chronic inflammatory airway disease.
  8. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society Guidelines for the Management of Adult Bronchiectasis. European Respiratory Journal. 2017.Guideline support for macrolide therapy in bronchiectasis patients with frequent exacerbations.
  9. Chalmers JD, Chang AB, Chotirmall SH, Dhar R, McShane PJ. Bronchiectasis. Nature Reviews Disease Primers. 2018.Supports bronchiectasis inflammatory biology and treatment context, including macrolide use.
Tetracyclines and Doxycycline in Pulmonary Disease7 references
  1. Allinson JP, Vlies BH, Brill SE, et al. Doxycycline for the Prevention of COPD Exacerbations: A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 2023.Supports the definitive COPD doxycycline trial; no significant overall reduction in exacerbations, with possible subgroup signal.
  2. Bhattacharyya P, Singh B, Sarkar S, et al. Impact of Long-Term Doxycycline on Lung Function and Exacerbations: A Real-World Open, Prospective Pilot Observation on Chronic Obstructive Pulmonary Disease. Indian Journal of Medical Research. 2021.Supports observational doxycycline data in COPD.
  3. Gu Y, Lee HM, Sorsa T, et al. Non-Antibacterial Tetracyclines Modulate Mediators of Periodontitis and Atherosclerotic Cardiovascular Disease. Pharmacological Research. 2011;64(6):573-579.Supports non-antibacterial tetracycline mechanisms, including MMP inhibition and systemic inflammatory mediator effects.
  4. Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study. Mediators of Inflammation. 2015;2015:329418.Supports doxycycline’s anti-inflammatory effects at low and high doses.
  5. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms. Advances in Dental Research. 1998.Supports tetracycline MMP inhibition relevant to extracellular matrix and lung structural remodeling.
  6. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial Dose Doxycycline as Adjunctive Treatment for Periodontitis: A Review. Journal of Clinical Periodontology. 2004;31(9):697-707.Supports sub-antimicrobial doxycycline as host-modulation therapy.
  7. Walker C, Preshaw PM, Novak J, Hefti AF, Bradshaw M, Powala C. Long-Term Treatment With Sub-Antimicrobial Dose Doxycycline Has No Antibacterial Effect on Intestinal Flora. Journal of Clinical Periodontology. 2005;32(11):1163-1169.Supports long-term sub-antimicrobial doxycycline safety regarding flora and resistance.
Roflumilast and PDE4 Inhibition4 references
  1. Calverley PMA, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in Symptomatic Chronic Obstructive Pulmonary Disease: Two Randomised Clinical Trials. Lancet. 2009;374(9691):685-694.Supports roflumilast reducing COPD exacerbations in selected patients with chronic bronchitis and severe COPD.
  2. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in Moderate-to-Severe Chronic Obstructive Pulmonary Disease Treated With Longacting Bronchodilators: Two Randomised Clinical Trials. Lancet. 2009;374(9691):695-703.Supports roflumilast as add-on therapy in COPD.
  3. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The Preclinical Pharmacology of Roflumilast — A Selective, Oral Phosphodiesterase 4 Inhibitor in Development for Chronic Obstructive Pulmonary Disease. Pulmonary Pharmacology & Therapeutics. 2010;23(4):235-256.Supports roflumilast’s PDE4/cAMP anti-inflammatory mechanism, including effects on inflammatory cells and cytokines.
  4. Rabe KF. Update on Roflumilast, a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. British Journal of Pharmacology. 2011;163(1):53-67.Review supporting roflumilast mechanism, efficacy, and limitations.
Theophylline and Low-Dose Anti-Inflammatory Mechanisms4 references
  1. Mokra D, Mokry J, Matasova K. Phosphodiesterase Inhibitors: Potential Role in the Respiratory Distress of Neonates. Pediatric Pulmonology. 2018.Supports methylxanthine and PDE-related anti-inflammatory mechanisms.
  2. Barnes PJ. Theophylline. American Journal of Respiratory and Critical Care Medicine. 2013;188(8):901-906.Supports theophylline’s respiratory pharmacology and low-dose anti-inflammatory mechanisms.
  3. Ito K, Lim S, Caramori G, et al. A Molecular Mechanism of Action of Theophylline: Induction of Histone Deacetylase Activity to Decrease Inflammatory Gene Expression. Proceedings of the National Academy of Sciences USA. 2002;99(13):8921-8926.Supports low-dose theophylline effects on histone deacetylase activity and inflammatory gene expression.
  4. Barnes PJ. Theophylline in Chronic Obstructive Pulmonary Disease: New Horizons. Proceedings of the American Thoracic Society. 2005;2(4):334-339.Supports low-dose theophylline as an anti-inflammatory strategy in COPD.
Inhaled Corticosteroids and Local Airway Inflammation3 references
  1. Barnes PJ. Corticosteroid Resistance in Patients With Asthma and Chronic Obstructive Pulmonary Disease. Journal of Allergy and Clinical Immunology. 2013;131(3):636-645.Supports corticosteroid anti-inflammatory effects and limitations in COPD.
  2. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled Corticosteroids in COPD and the Risk of Serious Pneumonia. Thorax. 2013;68(11):1029-1036.Supports pneumonia-risk caution with inhaled corticosteroids in COPD.
  3. Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled Corticosteroids for Stable Chronic Obstructive Pulmonary Disease.Cochrane Database of Systematic Reviews. 2012.Supports inhaled corticosteroid use and limitations in stable COPD.
Statins and Pulmonary Disease4 references
  1. Walsh A, Perrem L, Khashan AS, Henry MT, Ni Chroinin M. Statins Versus Placebo for People With Chronic Obstructive Pulmonary Disease.Cochrane Database of Systematic Reviews. 2019.Supports mixed evidence for statins in COPD, including limitations of randomized evidence.
  2. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. New England Journal of Medicine. 2014;370(23):2201-2210.STATCOPE trial; supports the negative randomized trial evidence for simvastatin in COPD patients without a cardiovascular indication.
  3. Schenk P, Spiel AO, Hüttinger F, et al. Can Simvastatin Reduce COPD Exacerbations? A Randomised Double-Blind Controlled Study. European Respiratory Journal. 2021.Supports a trial signal for reduced COPD exacerbations with simvastatin.
  4. Liu Y, Lu F, Wang B, et al. Statins and the Risk of COPD Exacerbation: ASystematic Review and Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2026.Supports recent synthesis suggesting possible reduction in severe exacerbations and hospitalization rates.
Colchicine and Pulmonary Inflammation3 references
  1. Dupuis J, Sirois MG, Rhéaume E, et al. Colchicine Reduces Lung Injury in Experimental Acute Respiratory Distress Syndrome. PLoS One. 2020.Supports colchicine effects on lung injury, edema, oxygenation, and neutrophil-mediated pulmonary inflammation.
  2. Tardif JC, Bouabdallaoui N, L’Allier PL, et al. Colchicine for Community-Treated Patients With COVID-19 (COLCORONA): A Phase 3, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicentre Trial. Lancet Respiratory Medicine. 2021.Supports colchicine data in community-treated COVID-19 and pneumonia/hospitalization outcomes.
  3. Kelly SJ, Uri AJ, Freeland HS, et al. Effects of Colchicine on IgE-Mediated Early and Late Airway Reactions. Chest. 1995.Supports colchicine effects on allergen-induced airway reactions.
Obstructive Sleep Apnea, Obesity, and Incretin Therapy3 references
  1. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 2024.SURMOUNT-OSA trial; supports tirzepatide reducing apnea-hypopnea index in adults with obesity and OSA.
  2. Bardóczi A, Matics ZZ, Turan C, et al. Efficacy of Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: ASystematic Review and Meta-Analysis of Randomized Controlled Trials. Sleep Medicine Reviews. 2025.Supports incretin-based therapy effects on obesity-related OSA.
  3. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-Like Receptor Agonists and Next-Generation Incretin-Based Medications: Metabolic, Cardiovascular, and Renal Benefits. Lancet. 2026.Supports broader incretin-based therapy context relevant to obesity, cardiometabolic disease, and OSA.
Indoor Air Quality, Environmental Exposure, and Pulmonary Reserve3 references
  1. Alford KL, Kumar N. Pulmonary Health Effects of Indoor Volatile Organic Compounds: A Meta-Analysis. International Journal of Environmental Research and Public Health. 2021.Supports indoor volatile organic compounds as pulmonary risk factors.
  2. Karr G, Quivet E, Ramel M, Nicolas M. Sprays and Diffusers as Indoor Air Fresheners: Exposure and Health Risk Assessment Based on Measurements Under Realistic Indoor Conditions. Indoor Air. 2022.Supports discussion of sprays, diffusers, indoor air fresheners, and inhaled exposure.
  3. Elliott L, Longnecker MP, Kissling GE, London SJ. Volatile Organic Compounds and Pulmonary Function in the Third National Health and Nutrition Examination Survey, 1988–1994. Environmental Health Perspectives. 2006.Supports association between volatile organic compound exposure and pulmonary function.
Respiratory Vaccines and Older Adults3 references
  1. Sumsuzzman DM, Shi C, Moghadas SM. Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus inOlder Adults: A Meta-Analysis. Clinical Infectious Diseases. 2026.Supports RSV vaccine effectiveness in older adults.
  2. Moser ITK, Dobrescu AI, Sommer I, et al. Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A RapidReview for the American College of Physicians. Annals of Internal Medicine. 2026.Supports RSV vaccine evidence and safety context in adults.
  3. Centers for Disease Control and Prevention. Adult Immunization Schedule.Supports influenza, pneumococcal, RSV, COVID-19, Tdap, shingles, and other adult vaccine recommendations.
Pulmonary Safety and Cautions4 references
  1. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the Risk of Cardiovascular Death. New England Journal of Medicine. 2012;366(20):1881-1890.Supports QT/cardiovascular caution with azithromycin in higher-risk patients.
  2. Svanström H, Pasternak B, Hviid A. Use of Azithromycin and Death From Cardiovascular Causes. New England Journal of Medicine. 2013;368(18):1704-1712.Supports additional cardiovascular safety context for azithromycin.
  3. Albert RK, Connett J, Bailey WC, et al. Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine. 2011;365(8):689-698.Also supports hearing decrement and antimicrobial resistance cautions during chronic azithromycin use.
  4. Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD Exacerbations: A European Respiratory Society / American Thoracic Society Guideline. European Respiratory Journal. 2017.Also supports careful patient selection and monitoring for long-term macrolide therapy.
CNS, Neuroimmune, and Brain-Related Medications56 references
Low-Dose Naltrexone5 references
  1. Zhou MH, Elston DM, Morrison BW, Lipner SR. Low-Dose Naltrexone for Treatment of Dermatologic Conditions: A Clinical Review. Journal of the American Academy of Dermatology. 2025.Supports low-dose naltrexone as an off-label immune-modulating therapy in inflammatory conditions.
  2. Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn’s Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018.Supports low-dose naltrexone safety and small-study evidence in chronic pain and inflammatory conditions.
  3. Cant R, Dalgleish AG, Allen RL. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets Following Stimulation With Ligands for Intracellular Toll-Like Receptors. Frontiers in Immunology. 2017.Supports naltrexone effects on IL-6, TNF-α, and intracellular Toll-like receptor pathways.
  4. Kwilasz AJ, Todd LS, Duran-Malle JC, et al. Experimental Autoimmune Encephalopathy-Induced Hippocampal Neuroinflammation and Memory Deficits Are Prevented With the Non-Opioid TLR2/TLR4 Antagonist (+)-Naltrexone. Behavioural Brain Research. 2021.Supports preclinical TLR2/TLR4 antagonism, hippocampal neuroinflammation reduction, and memory-related effects.
  5. Younger J, Parkitny L, McLain D. The Use of Low-Dose Naltrexone as a Novel Anti-Inflammatory Treatment for Chronic Pain. Clinical Rheumatology. 2014.Review supporting the rationale for low-dose naltrexone in chronic pain and inflammatory states.
Bumetanide and NKCC1 / APOE4 Rationale5 references
  1. Boyarko B, Podvin S, Greenberg B, et al. Evaluation of Bumetanide as a Potential Therapeutic Agent for Alzheimer’s Disease. Frontiers in Pharmacology. 2023.Review supporting bumetanide as a potential Alzheimer’s disease repurposing candidate, while recognizing limitations.
  2. Taubes A, Nova P, Zalocusky KA, et al. Experimental and Real-World Evidence Supporting the Computational Repurposing of Bumetanide for APOE4-Related Alzheimer’s Disease. Nature Aging. 2021.Core reference supporting bumetanide’s APOE4-related computational, preclinical, and real-world EHR rationale.
  3. Ben-Ari Y. NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders. Trends in Neurosciences. 2017.Supports the broader NKCC1 chloride transporter rationale in neurologic and psychiatric disorders.
  4. Kaila K, Price TJ, Payne JA, Puskarjov M, Voipio J. Cation-Chloride Cotransporters in Neuronal Development, Plasticity and Disease. Nature Reviews Neuroscience. 2014.Supports the biology of NKCC1 / KCC2 chloride transporters, neuronal chloride balance, and GABA signaling.
  5. Hampel H, Vergallo A, Perry G, et al. The Alzheimer Precision Medicine Initiative. Journal of Alzheimer’s Disease. 2019.Supports precision-medicine framing in Alzheimer’s disease and risk-stratified approaches such as APOE-related biology.
GLP-1 Receptor Agonists, Tirzepatide, and Neuroinflammation7 references
  1. Tang H, Donahoo WT, DeKosky ST, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias. JAMA Neurology. 2025.Supports observational and clinical interest in GLP-1 receptor agonists and SGLT2 inhibitors in Alzheimer disease and related dementias.
  2. Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S. The Promise of GLP-1 Receptor Agonists for Neurodegenerative Diseases. Journal of Clinical Investigation. 2026.Review supporting GLP-1 receptor agonists as neurodegeneration candidates through metabolic and neuroimmune mechanisms.
  3. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-Like Receptor Agonists and Next-Generation Incretin-Based Medications: Metabolic, Cardiovascular, and Renal Benefits. Lancet. 2026.Supports broad incretin biology and systemic metabolic benefits relevant to brain health.
  4. Cummings JL, Atri A, Sano M, et al. Efficacy and Safety of Oral Semaglutide 14 mg in Early-Stage Symptomatic Alzheimer’s Disease (EVOKE and EVOKE+): Two Phase 3, Randomised, Placebo-Controlled Trials. Lancet. 2026.Supports the important negative or neutral trial evidence for semaglutide in established early symptomatic Alzheimer’s disease.
  5. Hölscher C. Novel Dual GLP-1/GIP Receptor Agonists Show Neuroprotective Effects in Alzheimer’s and Parkinson’s Disease Models. Neuropharmacology. 2020.Supports preclinical rationale for dual incretin signaling and neuroprotection.
  6. During MJ, Cao L, Zuzga DS, et al. Glucagon-Like Peptide-1 Receptor Is Involved in Learning and Neuroprotection. Nature Medicine. 2003.Supports early GLP-1 receptor biology in learning and neuroprotection.
  7. Perry T, Lahiri DK, Chen D, et al. A Novel Neurotrophic Property of Glucagon-Like Peptide 1: A Promoter of Nerve Growth Factor-Mediated Differentiation in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics. 2002.Supports GLP-1 neurotrophic signaling.
Minocycline and CNS Anti-Inflammatory Effects7 references
  1. Möller T, Bard F, Bhattacharya A, et al. Critical Data-Based Re-Evaluation of Minocycline as a Putative Specific Microglia Inhibitor. Glia. 2016;64(10):1788-1794.Supports careful interpretation of minocycline as a microglial inhibitor and cautions against overstating specificity.
  2. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. Tetracyclines Inhibit Microglial Activation and Are Neuroprotective in Global Brain Ischemia. Proceedings of the National Academy of Sciences USA. 1998.Supports tetracyclines, including minocycline, as microglial anti-inflammatory and neuroprotective agents in preclinical ischemia models.
  3. Lu Y, Yang Y, Chen W, et al. Minocycline, but Not Doxycycline, Attenuates NMDA-Induced Intracellular Calcium and Excitotoxicity. NeuroReport. 2021.Supports within-class CNS distinction between minocycline and doxycycline.
  4. Chung CL, Tsai HP, Huang YH, et al. Attenuation in Proinflammatory Factors and Reduction in Neuronal Cell Apoptosis and Cerebral Vasospasm by Minocycline During Early Phase After Subarachnoid Hemorrhage in the Rat. BioMed Research International. 2021.Supports minocycline effects on neuroinflammation and neuronal injury.
  5. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline Inhibits Poly(ADP-Ribose) Polymerase-1 at Nanomolar Concentrations. Proceedings of the National Academy of Sciences USA. 2006.Supports minocycline PARP-1 inhibition as a CNS-relevant mechanism.
  6. Yong VW, Wells J, Giuliani F, et al. The Promise of Minocycline in Neurology. Lancet Neurology. 2004.Review supporting minocycline as a neurologic anti-inflammatory candidate.
  7. Garrido-Mesa J, Rodríguez-Nogales A, Algieri F, et al. Immunomodulatory Tetracyclines Shape the Intestinal Inflammatory Response Inducing Mucosal Healing and Resolution. British Journal of Pharmacology. 2018.Supports tetracycline immunomodulation and mucosal inflammatory effects relevant to gut-brain inflammatory biology.
Gabapentin, Pregabalin, and Neuroinflammatory Pain4 references
  1. Yamaguchi K, Kumakura S, Someya A, et al. Anti-Inflammatory Actions of Gabapentin and Pregabalin on the Substance P-Induced Mitogen-Activated Protein Kinase Activation in U373 MG Human Glioblastoma Astrocytoma Cells. Molecular Medicine Reports. 2017.Supports gabapentin and pregabalin effects on substance P-induced MAPK and NF-κB-related inflammatory signaling.
  2. de Brito TV, Júnior GJD, da Cruz Júnior JS, et al. Gabapentin Attenuates Intestinal Inflammation: Role of PPAR-γ Receptor. European Journal of Pharmacology. 2020.Supports gabapentin effects on inflammation through PPARγ-related mechanisms.
  3. Tomić M, Pecikoza U, Micov A, Vučković S, Stepanović-Petrović R. Antiepileptic Drugs as Analgesics / Adjuvants in Inflammatory Pain: Current Preclinical Evidence. Pharmacology & Therapeutics. 2018.Review supporting antiepileptic/gabapentinoid drugs as analgesics and adjuncts in inflammatory pain models.
  4. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for Neuropathic Pain in Adults: ASystematic Review and Meta-Analysis. Lancet Neurology. 2015.Supports gabapentin, pregabalin, duloxetine, and other neuropathic-pain drugs as evidence-based therapies, separate from their anti-inflammatory rationale.
SSRIs, SNRIs, Depression, and Neuroinflammation7 references
  1. Radtke FA, Chapman G, Hall J, Syed YA. Modulating Neuroinflammation to Treat Neuropsychiatric Disorders. BioMed Research International. 2017.Supports the broader concept of neuroinflammation as a treatment target in neuropsychiatric disorders.
  2. Takenaka Y, Tanaka R, Kitabatake K, et al. Profiling Differential Effects of 5 Selective Serotonin Reuptake Inhibitors on TLRs-Dependent and -Independent IL-6 Production in Immune Cells Identifies Fluoxetine as Preferred Anti-Inflammatory Drug Candidate. Frontiers in Pharmacology. 2022.Supports within-class SSRI differences in immune-cell inflammatory cytokine production.
  3. Takenaka Y, Tanaka R, Kitabatake K, et al. Structure-Activity Relationship Analysis of Fluoxetine for Suppression of Inflammatory Cytokine Production. Biological & Pharmaceutical Bulletin. 2024.Supports fluoxetine structure-activity relationships for cytokine suppression.
  4. Tynan RJ, Weidenhofer J, Hinwood M, et al. A Comparative Examination of the Anti-Inflammatory Effects of SSRI and SNRI Antidepressants on LPS-Stimulated Microglia. Brain, Behavior, and Immunity. 2012.Supports SSRI/SNRI effects on microglial inflammatory signaling.
  5. Du RH, Tan J, Sun XY, et al. Fluoxetine Inhibits NLRP3 Inflammasome Activation: Implication in Depression. International Journal of Neuropsychopharmacology. 2016;19(9):pyw037.Supports fluoxetine effects on NLRP3 inflammasome activation.
  6. Chen C, Zhang S, Sheng M, Shao W. NLRP3 Inflammasome: A New Target for the Treatment of Cardiovascular Disease and Depression Comorbidity. Mediators of Inflammation. 2025;2025:5511234.Supports NLRP3 as a link between cardiovascular disease and depression.
  7. Köhler-Forsberg O, N Lydholm C, Hjorthøj C, et al. Efficacy of Anti-Inflammatory Treatment on Major Depressive Disorder or Depressive Symptoms: Meta-Analysis of Clinical Trials. Acta Psychiatrica Scandinavica. 2019.Supports the broader inflammatory-depression treatment rationale.
Sleep, Physical Function, and Cognitive Reserve4 references
  1. Dam TT, Ewing S, Ancoli-Israel S, et al. Association Between Sleep and Physical Function inOlder Men: The Osteoporotic Fractures in Men Sleep Study. Journal of the American Geriatrics Society. 2008;56(9):1665-1673.Supports links between sleep quality and physical function in older men.
  2. Goldman SE, Stone KL, Ancoli-Israel S, et al. Poor Sleep Is Associated With Poorer Physical Performance and Greater Functional Limitations inOlder Women. Sleep. 2007;30(10):1317-1324.Supports the connection between sleep and functional decline in older women.
  3. Lim ASP, Yu L, Kowgier M, et al. Modification of the Relationship of the Apolipoprotein E ε4 Allele to the Risk of Alzheimer Disease and Neurofibrillary Tangle Density by Sleep. JAMA Neurology. 2013;70(12):1544-1551.Supports sleep as a modifier of APOE4-related Alzheimer’s disease risk.
  4. Xie L, Kang H, Xu Q, et al. Sleep Drives Metabolite Clearance From the Adult Brain. Science. 2013;342(6156):373-377.Supports sleep and glymphatic/metabolite clearance biology.
Cognitive Impairment, Dementia Risk, and Geriatric Medication Safety5 references
  1. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use inOlder Adults. Journal of the American Geriatrics Society. 2023.Supports avoidance or caution with anticholinergics, benzodiazepines, Z-drugs, antipsychotics, and other medications that may impair cognition or increase falls.
  2. Gray SL, Anderson ML, Dublin S, et al. Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study. JAMA Internal Medicine. 2015;175(3):401-407.Supports anticholinergic burden and dementia risk discussion.
  3. Richardson K, Fox C, Maidment I, et al. Anticholinergic Drugs and Risk of Dementia: Case-Control Study. BMJ. 2018;361:k1315.Supports association between anticholinergic exposure and dementia risk.
  4. Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine Use and Risk of Alzheimer’s Disease: Case-Control Study. BMJ. 2014;349:g5205.Supports caution around benzodiazepines and dementia risk.
  5. By the 2023 AGS Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use inOlder Adults. Journal of the American Geriatrics Society. 2023.Duplicate if already used; can be cross-tagged under Safety rather than repeated in final website bibliography.
Stroke and Vascular Brain Protection4 references
  1. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2014.Supports secondary stroke prevention with antiplatelets, statins, and blood pressure control.
  2. Amarenco P, Bogousslavsky J, Callahan A III, et al. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2006;355(6):549-559.SPARCL trial; supports statin therapy in secondary stroke prevention.
  3. PROGRESS Collaborative Group. Randomised Trial of a Perindopril-Based Blood-Pressure-Lowering Regimen Among 6,105 Individuals With Previous Stroke or Transient Ischaemic Attack. Lancet. 2001;358(9287):1033-1041.Supports blood pressure lowering for recurrent stroke prevention.
  4. Diener HC, Hankey GJ, Easton JD, et al. Dipyridamole Plus Aspirin Versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine. 2008;359(12):1238-1251.Supports antiplatelet therapy comparisons in recurrent stroke prevention.
Parkinson’s Disease and Gut-Brain / Neurodegeneration Context4 references
  1. Bloem BR, Okun MS, Klein C. Parkinson’s Disease. Lancet. 2021;397(10291):2284-2303.Broad clinical review supporting Parkinson’s disease biology and treatment context.
  2. Poewe W, Seppi K, Tanner CM, et al. Parkinson Disease. Nature Reviews Disease Primers. 2017;3:17013.Supports Parkinson’s disease pathophysiology and neurodegeneration context.
  3. Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson’s Disease. Lancet Neurology. 2015;14(6):625-639.Supports gut dysfunction and constipation as relevant to Parkinson’s disease.
  4. Chen H, Zhao EJ, Zhang W, et al. Meta-Analyses on Prevalence of Selected Parkinson’s Nonmotor Symptoms Before and After Diagnosis. Translational Neurodegeneration. 2015;4:1.Supports nonmotor symptoms such as constipation and sleep disturbance in Parkinson’s disease.
Alzheimer’s Disease and Dementia Clinical Context4 references
  1. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s Disease. Lancet. 2021;397(10284):1577-1590.Broad clinical review supporting Alzheimer’s disease biology, risk factors, and treatment context.
  2. Livingston G, Huntley J, Sommerlad A, et al. Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission. Lancet. 2020;396(10248):413-446.Supports modifiable dementia risk factors and prevention framework.
  3. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease. Alzheimer’s & Dementia. 2018;14(4):535-562.Supports Alzheimer’s disease biomarker and biological framework.
  4. Bellenguez C, Küçükali F, Jansen IE, et al. New Insights Into the Genetic Etiology of Alzheimer’s Disease and Related Dementias. Nature Genetics. 2022;54(4):412-436.Supports genetic risk context, including APOE-related dementia biology.
GI, Endocrine, Renal-Adjacent, and Miscellaneous Common Medications58 references
Proton Pump Inhibitors8 references
  1. Kedika RR, Souza RF, Spechler SJ. Potential Anti-Inflammatory Effects of Proton Pump Inhibitors: AReview and Discussion of the Clinical Implications. Digestive Diseases and Sciences. 2009.Supports anti-inflammatory effects of PPIs beyond acid suppression.
  2. Paz MFCJ, de Alencar MVOB, de Lima RMP, et al. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxidative Medicine and Cellular Longevity. 2019.Supports broader pharmacologic and oxidative-stress-related effects of omeprazole.
  3. Abed MN, Alassaf FA, Jasim MHM, Alfahad M, Qazzaz ME. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole. Pharmacology. 2020.Supports within-class comparison of antioxidant effects among PPIs.
  4. Takagi T, Naito Y, Okada H, et al. Lansoprazole, a Proton Pump Inhibitor, Mediates Anti-Inflammatory Effect in Gastric Mucosal Cells Through the Induction of Heme Oxygenase-1 via Activation of NF-E2-related Factor 2 and Oxidation of Kelch-Like ECH-associating Protein 1. Journal of Pharmacology and Experimental Therapeutics. 2009.Supports lansoprazole effects on Nrf2, Keap1, and heme oxygenase-1.
  5. Kikuchi S, Imai H, Tani Y, Tajiri T, Watanabe N. Proton Pump Inhibitors for Chronic Obstructive Pulmonary Disease.Cochrane Database of Systematic Reviews. 2020.Supports the limited and disease-specific evidence for PPIs beyond acid suppression.
  6. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-Term Use of Proton Pump Inhibitors: ExpertReview and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017.Supports long-term PPI safety cautions and best-practice use.
  7. Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine. 2016;176(2):238-246.Supports observational kidney-risk discussion with long-term PPI use.
  8. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology. 2016;27(10):3153-3163.Supports PPI kidney-risk caution in observational data.
Pentoxifylline7 references
  1. Brie D, Sahebkar A, Penson PE, et al. Effects of Pentoxifylline on Inflammatory Markers and Blood Pressure: ASystematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Hypertension. 2016.Supports pentoxifylline reduction of TNF-α and CRP across randomized trials.
  2. Jayathilaka EHTT, Kim MM. Methylxanthine Derivative, Pentoxifylline Attenuates Inflammation via NF-κB and AP-1 Pathway Inhibition in Murine Macrophages. Journal of Bioscience and Bioengineering. 2026.Supports pentoxifylline effects on NF-κB and AP-1 inflammatory pathways.
  3. Speer EM, Dowling DJ, Ozog LS, et al. Pentoxifylline Inhibits TLR- and Inflammasome-Mediated In Vitro Inflammatory Cytokine Production in Human Blood With Greater Efficacy and Potency in Newborns. Pediatric Research. 2017.Supports pentoxifylline effects on TLR and inflammasome-mediated cytokine production.
  4. Noureddin M, Anstee QM, Loomba R. Review Article: Emerging Anti-Fibrotic Therapies in the Treatment of Non-Alcoholic Steatohepatitis. Alimentary Pharmacology & Therapeutics. 2016.Supports pentoxifylline and anti-fibrotic therapy context in NASH/MASH.
  5. Grammatis AL, Georgiou EX, Becker CM. Pentoxifylline for the Treatment of Endometriosis-Associated Pain and Infertility.Cochrane Database of Systematic Reviews. 2021.Supports pentoxifylline clinical-trial context in inflammatory conditions, while also showing limits of evidence.
  6. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Pentoxifylline Reduces Proteinuria in Patients With Diabetic Nephropathy. Kidney International. 2006.Supports pentoxifylline kidney and proteinuria context.
  7. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Chahin J, Méndez ML, Gallego E. Effect of Pentoxifylline on Renal Function and Urinary Albumin Excretion in Patients With Diabetic Kidney Disease. Journal of the American Society of Nephrology. 2015.Supports pentoxifylline in diabetic kidney disease and inflammatory renal context.
PDE5 Inhibitors5 references
  1. Laxmi V, Gupta R, Bhattacharya SK, Ray A, Gulati K. Inhibitory Effects of Sildenafil and Tadalafil on Inflammation, Oxidative Stress and Nitrosative Stress in Animal Model of Bronchial Asthma. Pharmacological Reports. 2019.Supports sildenafil and tadalafil effects on inflammation, oxidative stress, and nitrosative stress.
  2. Paronetto MP, Crescioli C. Rethinking of Phosphodiesterase 5 Inhibition: The Old, the New and the Perspective in Human Health. Frontiers in Endocrinology. 2024.Review supporting PDE5 inhibition beyond erectile dysfunction, including vascular and inflammatory biology.
  3. Peixoto CA, Nunes AK, Garcia-Osta A. Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. Mediators of Inflammation. 2015.Supports PDE5 inhibitor effects on neuroinflammatory and neurodegenerative signaling pathways.
  4. Giannetta E, Feola T, Gianfrilli D, et al. Is Chronic Inhibition of Phosphodiesterase Type 5 Cardioprotective and Safe? A Meta-Analysis of Randomized Controlled Trials. BMC Medicine. 2014.Supports cardiovascular and safety context for PDE5 inhibitor use.
  5. Vlachopoulos C, Ioakeimidis N, Rokkas K, et al. Acute Effect of Sildenafil on Inflammatory Markers / Endothelial Function in Patients With Erectile Dysfunction and Cardiovascular Risk Factors. International Journal of Cardiology. 2015.Supports PDE5 inhibitor effects in vascular/endothelial inflammatory context.
Levothyroxine and Thyroid-Related Inflammation9 references
  1. Tellechea ML. Meta-Analytic Evidence for Increased Low-Grade Systemic Inflammation and Oxidative Stress in Hypothyroid Patients. Can Levothyroxine Replacement Therapy Mitigate the Burden? Endocrine. 2021;72(1):62-71.Supports hypothyroidism as a pro-inflammatory and oxidative-stress state and levothyroxine as restorative therapy.
  2. Krysiak R, Okopień B. The Effect of Levothyroxine and Selenomethionine on Lymphocyte and Monocyte Cytokine Release in Women With Hashimoto's Thyroiditis. Journal of Clinical Endocrinology and Metabolism. 2011.Supports levothyroxine effects on immune-cell cytokine release in Hashimoto’s thyroiditis.
  3. Bilgir O, Bilgir F, Calan M, Calan OG, Yuksel A. Comparison of Pre- and Post-Levothyroxine High-Sensitivity C-Reactive Protein and Fetuin-A Levels in Subclinical Hypothyroidism. Clinics. 2015.Supports levothyroxine effects on hsCRP and inflammatory markers in subclinical hypothyroidism.
  4. Ates I, Altay M, Yilmaz FM, et al. The Impact of Levothyroxine Sodium Treatment on Oxidative Stress in Hashimoto's Thyroiditis. European Journal of Endocrinology. 2016;174(6):727-734.Supports levothyroxine effects on oxidative stress in Hashimoto’s thyroiditis.
  5. Ghosh H, Biswas D, Pramanik S, Chowdhury S. Analysis of Risk Factors and Predictive Modelling of Biomarkers in Subclinical Hypothyroidism and Implications for Levothyroxine Therapy in Disease Management. Scientific Reports. 2025;15(1):40946.Supports subclinical hypothyroidism, inflammatory biomarkers, and possible levothyroxine implications.
  6. de Castro AL, Fernandes RO, Ortiz VD, et al. Thyroid Hormones Decrease the Proinflammatory TLR4 / NF-κB Pathway and Improve Functional Parameters of the Left Ventricle of Infarcted Rats. Molecular and Cellular Endocrinology. 2018;461:132-142.Supports thyroid hormone effects on TLR4 / NF-κB inflammatory signaling in cardiac tissue.
  7. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751.Guideline support for levothyroxine as standard treatment and caution about overtreatment.
  8. Jasim S, Papaleontiou M. Considerations in the Diagnosis and Management of Thyroid Dysfunction inOlder Adults. Thyroid. 2025;35(6):624-632.Supports thyroid-treatment caution and age-specific considerations in older adults.
  9. Taylor PN, Medici MM, Hubalewska-Dydejczyk A, Boelaert K. Hypothyroidism. Lancet. 2024;404(10460):1347-1364.Broad clinical review of hypothyroidism, treatment, and modern management.
Amiloride and Potassium-Sparing Diuretics6 references
  1. Haddad JJ, Land SC. Amiloride Blockades Lipopolysaccharide-Induced Proinflammatory Cytokine Biosynthesis in an IκBα / NF-κB-Dependent Mechanism: Evidence for the Amplification of an Antiinflammatory Pathway in the Alveolar Epithelium. American Journal of Respiratory Cell and Molecular Biology. 2002.Supports amiloride effects on cytokine production and NF-κB-related inflammatory signaling.
  2. Thangaraj SS, Oxlund CS, Andersen H, et al. Amiloride Lowers Plasma TNF and Interleukin-6 but Not Interleukin-17A in Patients With Hypertension and Type 2 Diabetes. American Journal of Physiology-Renal Physiology. 2024.Supports human evidence that amiloride lowers TNF and IL-6 in patients with hypertension and type 2 diabetes.
  3. Haddad JJ. Amiloride and the Regulation of NF-κB: An Unsung Crosstalk and Missing Link Between Fluid Dynamics and Oxidative Stress-Related Inflammation — Controversy or Pseudo-Controversy? Biochemical and Biophysical Research Communications. 2005.Supports mechanistic discussion of amiloride, NF-κB, and oxidative stress-related inflammation.
  4. Kamachi F, Ban HS, Hirasawa N, Ohuchi K. Inhibition of Lipopolysaccharide-Induced Prostaglandin E2 Production and Inflammation by the Na+/H+ Exchanger Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 2007.Supports sodium/hydrogen exchanger inhibition and inflammatory mediator reduction.
  5. Gei L, Yan Y, Xing W, et al. Amiloride Alleviates Morphine Tolerance by Suppressing ASIC3-Dependent Neuroinflammation in the Spinal Cord. European Journal of Pharmacology. 2023.Supports amiloride effects on neuroinflammation in preclinical pain models.
  6. Wang X, Zhu Y, Zheng S, et al. Amiloride Inhibits Osteoclastogenesis by Suppressing Nuclear Factor-κB and Mitogen-Activated Protein Kinase Activity in Receptor Activator of Nuclear Factor-κB-Induced RAW264.7 Cells. Molecular Medicine Reports. 2015.Supports amiloride effects on NF-κB, MAPK, and osteoclastogenesis.
Alpha-Blockers and BPH Medications5 references
  1. Roehrborn CG. Benign Prostatic Hyperplasia: An Overview. Reviews in Urology. 2005.General BPH pharmacology context for alpha-blockers and 5-alpha reductase inhibitors.
  2. Nickel JC. Inflammation and Benign Prostatic Hyperplasia. Urologic Clinics of North America. 2008;35(1):109-115.Supports inflammatory context in BPH.
  3. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUAGuideline on the Management of Benign Prostatic Hyperplasia. Journal of Urology. 2011.Guideline support for BPH medication context.
  4. Lepor H. Alpha Blockers for the Treatment of Benign Prostatic Hyperplasia. Reviews in Urology. 2007.Supports alpha-blocker class context and safety considerations.
  5. Nickel JC, Roehrborn CG, O’Leary MP, et al. The Relationship Between Prostate Inflammation and Lower Urinary Tract Symptoms. Journal of Urology. 2008.Supports the connection between prostate inflammation and urinary symptoms.
Antifibrotics9 references
  1. Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease. American Journal of Respiratory Cell and Molecular Biology. 2020;62(4):413-422.Supports pirfenidone anti-inflammatory and antifibrotic mechanisms.
  2. Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2018;378(19):1811-1823.Broad clinical reference for idiopathic pulmonary fibrosis, pirfenidone, and nintedanib.
  3. Richeldi L, Collard HR, Jones MG. Idiopathic Pulmonary Fibrosis. Lancet. 2017;389(10082):1941-1952.Broad IPF review supporting antifibrotic therapy context.
  4. Kahvecioglu D. Molecular Pathways in Idiopathic Pulmonary Fibrosis: AReview of Novel Insights for Drug Design. Drug Development Research. 2025;86(3):e70094.Supports molecular pathways in pulmonary fibrosis and drug design.
  5. Fois AG, Sotgiu E, Scano V, et al. Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients With Idiopathic Pulmonary Fibrosis: A Preliminary Report. Antioxidants. 2020;9(11):E1064.Supports pirfenidone and nintedanib effects on systemic oxidative stress and inflammatory markers.
  6. Abdulaal WH, Omar UM, Zeyadi M, et al. Pirfenidone Ameliorates ANIT-Induced Cholestatic Liver Injury via Modulation of FXR, NF-κB / TNF-α, and WNT / GSK-3β / β-Catenin Signaling Pathways. Toxicology and Applied Pharmacology. 2024;490:117038.Supports pirfenidone effects on NF-κB / TNF-α signaling in liver injury models.
  7. Wanas H, Mekawy DM, Raafat Hamed RM, et al. Anti-Inflammatory Effect of Pirfenidone Compared to Dexamethasone in Ulcerative Colitis Model Induced by Acetic Acid in Rats: Involvement of miR-146a and TLR4 / NF-κB Signaling. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025.Supports pirfenidone effects on TLR4 / NF-κB inflammatory signaling.
  8. Ramírez-Mejía MM, Ponciano-Rodríguez G, Poo JL, Méndez-Sánchez N. Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence. Archives of Medical Research. 2026;57(4):103387.Supports pirfenidone as an antifibrotic candidate in metabolic steatohepatitis.
  9. Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023.Already relevant to cardiovascular/loop diuretics; can be cross-tagged here if torsemide antifibrotic biology is discussed.
Kidney-Adjacent Medication Safety and Monitoring5 references
  1. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent Use of Diuretics, Angiotensin Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers With NSAIDs and Risk of Acute Kidney Injury: Nested Case-Control Study. BMJ. 2013;346:e8525.Supports “triple whammy” kidney safety warning.
  2. Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case-Control Study. PLoS One. 2015;10(4):e0122899.Supports NSAID and CKD risk discussion.
  3. American Diabetes Association / KDIGO Consensus Report. Diabetes Management in Chronic Kidney Disease. Diabetes Care. 2022.Supports metformin, SGLT2 inhibitor, GLP-1 receptor agonist, and kidney monitoring framework.
  4. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2024.Supports kidney staging, medication caution, and CKD management context.
  5. KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022.Supports diabetes and CKD medication framework including SGLT2 inhibitors, metformin, and GLP-1 receptor agonists.
General Medication Safety and Geriatric Context4 references
  1. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use inOlder Adults. Journal of the American Geriatrics Society. 2023.Supports geriatric medication safety, falls, anticholinergics, NSAID caution, sedatives, and drug-risk language.
  2. By the 2023 AGS Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use inOlder Adults. Journal of the American Geriatrics Society. 2023.Duplicate listing if already included elsewhere; final website version should keep only one Beers Criteria citation and cross-tag it under Safety.
  3. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP / START Criteria for Potentially Inappropriate Prescribing inOlder People: Version 2. Age and Ageing. 2015;44(2):213-218.Supports geriatric prescribing and medication optimization context.
  4. Hanlon JT, Schmader KE. The Medication Appropriateness Index at 20: Where It Started, Where It Has Been, and Where It May Be Going. Drugs & Aging. 2013;30(11):893-900.Supports medication appropriateness and older-adult prescribing framework.
Pathway Foundations, Inflammaging, Sarcopenia, and Loss of Reserve58 references
Inflammaging and Age-Related Disease8 references
  1. Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging: An Evolutionary Perspective on Immunosenescence. Annals of the New York Academy of Sciences. 2000;908:244-254.Foundational paper introducing the concept of inflammaging.
  2. Franceschi C, Campisi J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2014;69(Suppl 1):S4-S9.Supports chronic low-grade inflammation as a contributor to age-associated disease.
  3. Ferrucci L, Fabbri E. Inflammageing: Chronic Inflammation in Ageing, Cardiovascular Disease, and Frailty. Nature Reviews Cardiology. 2018;15(9):505-522.Supports the link between inflammaging, cardiovascular disease, frailty, and functional decline.
  4. Furman D, Campisi J, Verdin E, et al. Chronic Inflammation in the Etiology of Disease Across the Life Span. Nature Medicine. 2019;25(12):1822-1832.Broad review supporting chronic inflammation as a driver across multiple diseases and age groups.
  5. Xia S, Zhang X, Zheng S, et al. An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment. Journal of Immunology Research. 2016;2016:8426874.Review of inflammaging mechanisms and potential interventions.
  6. Fulop T, Larbi A, Witkowski JM, et al. Aging, Frailty and Age-Related Diseases. Biogerontology. 2010;11(5):547-563.Supports the connection between aging biology, frailty, and age-related disease.
  7. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell. 2013;153(6):1194-1217.Broad aging-biology reference supporting chronic inflammation, cellular damage, mitochondrial dysfunction, and loss of tissue maintenance.
  8. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of Aging: An Expanding Universe. Cell. 2023;186(2):243-278.Updated aging-biology reference supporting the expanded framework of aging mechanisms.
Cytokine Signaling / NF-κB8 references
  1. Lawrence T. The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harbor Perspectives in Biology. 2009;1(6):a001651.Core reference explaining NF-κB as a central inflammatory pathway.
  2. Hayden MS, Ghosh S. Shared Principles in NF-κB Signaling. Cell. 2008;132(3):344-362.Supports NF-κB signaling biology and its role in inflammatory gene regulation.
  3. Hayden MS, Ghosh S. NF-κB in Immunobiology. Cell Research. 2011;21(2):223-244.Supports NF-κB as a major immune and inflammatory transcriptional regulator.
  4. Liu T, Zhang L, Joo D, Sun SC. NF-κB Signaling in Inflammation. Signal Transduction and Targeted Therapy. 2017;2:17023.Modern review supporting NF-κB’s central role in inflammation.
  5. Karin M, Greten FR. NF-κB: Linking Inflammation and Immunity to Cancer Development and Progression. Nature Reviews Immunology. 2005;5(10):749-759.Supports NF-κB as a bridge between chronic inflammation and tissue pathology.
  6. Baker RG, Hayden MS, Ghosh S. NF-κB, Inflammation, and Metabolic Disease. Cell Metabolism. 2011;13(1):11-22.Supports the connection between NF-κB, inflammation, insulin resistance, and metabolic disease.
  7. Li H, Malhotra S, Kumar A. Nuclear Factor-Kappa B Signaling in Skeletal Muscle Atrophy. Journal of Molecular Medicine. 2008;86(10):1113-1126.Supports NF-κB signaling in muscle atrophy and muscle protein breakdown.
  8. Cai D, Frantz JD, Tawa NE Jr, et al. IKKβ / NF-κB Activation Causes Severe Muscle Wasting in Mice. Cell. 2004;119(2):285-298.Supports a direct mechanistic link between NF-κB activation and muscle wasting.
NLRP3 Inflammasome10 references
  1. Schroder K, Tschopp J. The Inflammasomes. Cell. 2010;140(6):821-832.Foundational review of inflammasome biology.
  2. Guo H, Callaway JB, Ting JPY. Inflammasomes: Mechanism of Action, Role in Disease, and Therapeutics. Nature Medicine. 2015;21(7):677-687.Supports inflammasome mechanisms, disease links, and therapeutic targeting.
  3. Swanson KV, Deng M, Ting JPY. The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics. Nature Reviews Immunology. 2019;19(8):477-489.Core reference for NLRP3 activation, regulation, and therapeutic relevance.
  4. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. International Journal of Molecular Sciences. 2019;20(13):3328.Supports NLRP3 activation mechanisms and regulation.
  5. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-Associated Uric Acid Crystals Activate the NALP3 Inflammasome. Nature. 2006;440(7081):237-241.Core reference linking uric acid crystals to NLRP3 inflammasome activation.
  6. Duewell P, Kono H, Rayner KJ, et al. NLRP3 Inflammasomes Are Required for Atherogenesis and Activated by Cholesterol Crystals. Nature. 2010;464(7293):1357-1361.Supports cholesterol crystal activation of NLRP3 in atherosclerosis.
  7. Tschopp J, Schroder K. NLRP3 Inflammasome Activation: The Convergence of Multiple Signalling Pathways on ROS Production? Nature Reviews Immunology. 2010;10(3):210-215.Supports oxidative stress as a converging signal for NLRP3 activation.
  8. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression. Journal of Immunology. 2009;183(2):787-791.Supports the two-signal model linking NF-κB priming to NLRP3 activation.
  9. Chauhan D, Vande Walle L, Lamkanfi M. Therapeutic Modulation of Inflammasome Pathways. Immunological Reviews. 2020;297(1):123-138.Supports therapeutic targeting of inflammasome pathways.
  10. Jimenez-Duran G, Triantafilou M. Metabolic Regulators of Inflammasomes in Autoimmune Diseases and Crosstalk With Innate Immune Receptors. Immunology. 2021.Supports the connection among metabolism, inflammasome activation, and innate immune signaling.
Oxidative Stress / ROS10 references
  1. Sies H. Oxidative Stress: A Concept in Redox Biology and Medicine. Redox Biology. 2015;4:180-183.Foundational reference on oxidative stress as a biological and medical concept.
  2. Schieber M, Chandel NS. ROS Function in Redox Signaling and Oxidative Stress. Current Biology. 2014;24(10):R453-R462.Supports the dual role of ROS as signaling molecules and mediators of oxidative damage.
  3. Liguori I, Russo G, Curcio F, et al. Oxidative Stress, Aging, and Diseases. Clinical Interventions in Aging. 2018;13:757-772.Review supporting oxidative stress as a contributor to aging and age-related disease.
  4. Finkel T, Holbrook NJ. Oxidants, Oxidative Stress and the Biology of Ageing. Nature. 2000;408(6809):239-247.Classic review on oxidative stress and aging biology.
  5. de Almeida AJPO, de Almeida Rezende MS, Dantas SH, et al. Unveiling the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular Diseases. Oxidative Medicine and Cellular Longevity. 2019.Supports the joint role of inflammation and oxidative stress in age-related cardiovascular disease.
  6. Förstermann U, Xia N, Li H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circulation Research. 2017;120(4):713-735.Supports vascular oxidative stress, nitric oxide disruption, and atherosclerosis.
  7. Brandes RP, Weissmann N, Schröder K. NADPH Oxidases in Cardiovascular Disease. Free Radical Biology and Medicine. 2010;49(5):687-706.Supports NADPH oxidase as a major vascular source of ROS.
  8. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of Oxidative Stress in Atherosclerosis. American Journal of Cardiology. 2003;91(3A):7A-11A.Supports oxidative stress in atherosclerosis and endothelial dysfunction.
  9. Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme. Current Medicinal Chemistry. 2016;23(34):4027-4036.Supports xanthine oxidoreductase biology relevant to oxidative stress and drug pathways.
  10. Okafor ON, Farrington K, Gorog DA. Allopurinol as a Therapeutic Option in Cardiovascular Disease. Pharmacology & Therapeutics. 2017;172:139-150.Supports xanthine oxidase inhibition, oxidative stress reduction, and cardiovascular relevance.
Sarcopenia, Frailty, and Loss of Physical Reserve14 references
  1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age and Ageing. 2019;48(1):16-31.EWGSOP2 consensus; supports sarcopenia as loss of muscle strength, muscle quantity/quality, and physical performance.
  2. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636-2646.Broad clinical review on sarcopenia.
  3. Morley JE, Anker SD, von Haehling S. Prevalence, Incidence, and Clinical Impact of Sarcopenia: Facts, Numbers, and Epidemiology — Update 2014. Journal of Cachexia, Sarcopenia and Muscle. 2014;5(4):253-259.Supports prevalence and clinical impact of sarcopenia.
  4. Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory Markers and Loss of Muscle Mass and Strength. American Journal of Medicine. 2006;119(6):526.e9-526.e17.Supports inflammatory markers as predictors of muscle loss and strength decline.
  5. Schaap LA, Pluijm SMF, Deeg DJH, et al. Higher Inflammatory Marker Levels inOlder Persons: Associations With 5-Year Change in Muscle Mass and Muscle Strength. Journals of Gerontology Series A. 2009;64A(11):1183-1189.Supports longitudinal connection between inflammation, muscle mass, and strength.
  6. Dalle S, Rossmeislova L, Koppo K. The Role of Inflammation in Age-Related Sarcopenia. Frontiers in Physiology. 2017;8:1045.Review supporting inflammation as a driver of sarcopenia.
  7. Bano G, Trevisan C, Carraro S, et al. Inflammation and Sarcopenia: ASystematic Review and Meta-Analysis. Maturitas. 2017;96:10-15.Supports association between inflammatory markers and sarcopenia.
  8. Visser M, Pahor M, Taaffe DR, et al. Relationship of Interleukin-6 and Tumor Necrosis Factor-α With Muscle Mass and Muscle Strength in Elderly Men and Women: The Health ABC Study. Journals of Gerontology Series A. 2002;57(5):M326-M332.Supports IL-6 and TNF-α association with muscle mass and strength in older adults.
  9. Ferrucci L, Penninx BWJH, Volpato S, et al. Change in Muscle Strength Explains Accelerated Decline of Physical Function inOlder Women With High Interleukin-6 Serum Levels. Journal of the American Geriatrics Society. 2002;50(12):1947-1954.Supports IL-6, strength decline, and loss of physical function.
  10. Cesari M, Penninx BWJH, Pahor M, et al. Inflammatory Markers and Physical Performance inOlder Persons: The InCHIANTI Study. Journals of Gerontology Series A. 2004;59(3):242-248.Supports inflammatory markers and physical performance decline.
  11. Walston J, McBurnie MA, Newman A, et al. Frailty and Activation of the Inflammation and Coagulation Systems With and Without Clinical Comorbidities: Results From the Cardiovascular Health Study. Archives of Internal Medicine. 2002;162(20):2333-2341.Supports inflammation and coagulation activation in frailty.
  12. Fried LP, Tangen CM, Walston J, et al. Frailty in Older Adults: Evidence for a Phenotype. Journals of Gerontology Series A. 2001;56(3):M146-M156.Foundational frailty phenotype paper.
  13. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in Elderly People. Lancet. 2013;381(9868):752-762.Broad clinical review of frailty.
  14. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: An Undiagnosed Condition inOlder Adults. Current Consensus Definition. Journal of the American Medical Directors Association. 2011;12(4):249-256.International consensus reference on sarcopenia.
Muscle Breakdown, Anabolic Resistance, and Recovery8 references
  1. Phillips SM. Nutritional Supplements in Support of Resistance Exercise to Counter Age-Related Sarcopenia. Advances in Nutrition. 2015;6(4):452-460.Supports protein, resistance exercise, and sarcopenia prevention.
  2. Morton RW, Traylor DA, Weijs PJM, Phillips SM. Defining Anabolic Resistance: Implications for Delivery of Clinical Care Nutrition. Current Opinion in Critical Care. 2018;24(2):124-130.Supports anabolic resistance concept.
  3. Breen L, Phillips SM. Skeletal Muscle Protein Metabolism in the Elderly: Interventions to Counteract the Anabolic Resistance of Ageing. Nutrition & Metabolism. 2011;8:68.Supports age-related anabolic resistance and intervention logic.
  4. Wall BT, Gorissen SH, Pennings B, et al. Aging Is Accompanied by a Blunted Muscle Protein Synthetic Response to Protein Ingestion. PLoS One. 2015;10(11):e0140903.Supports reduced muscle protein synthetic response in aging.
  5. Burd NA, Gorissen SH, van Loon LJC. Anabolic Resistance of Muscle Protein Synthesis With Aging. Exercise and Sport Sciences Reviews. 2013;41(3):169-173.Supports anabolic resistance as an aging-muscle problem.
  6. Dickinson JM, Drummond MJ, Coben JR, Volpi E, Rasmussen BB. Aging Differentially Affects Human Skeletal Muscle Amino Acid Transporter Expression When Essential Amino Acids Are Ingested After Exercise. Clinical Nutrition. 2013;32(2):273-280.Supports aging-related differences in muscle response to protein and exercise.
  7. Fry CS, Drummond MJ, Glynn EL, et al. Aging Impairs Contraction-Induced Human Skeletal Muscle mTORC1 Signaling and Protein Synthesis. Skeletal Muscle. 2011;1(1):11.Supports impaired mTORC1/protein synthesis response with aging.
  8. Bosaeus I, Rothenberg E. Nutrition and Physical Activity for the Prevention and Treatment of Age-Related Sarcopenia. Proceedings of the Nutrition Society. 2016;75(2):174-180.Supports nutrition and physical activity as core sarcopenia interventions.
Muscle Reserve Check References6 references
SARC-F / Functional Sarcopenia Screening3 references
  1. Malmstrom TK, Morley JE. SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. Journal of the American Medical Directors Association. 2013;14(8):531-532.Core SARC-F reference. Supports the five-question screening structure: strength, assistance walking, rising from a chair, climbing stairs, and falls.
  2. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: A Symptom Score to Predict Persons With Sarcopenia at Risk for Poor Functional Outcomes. Journal of Cachexia, Sarcopenia and Muscle. 2015;6(1):28-36.Supports SARC-F as a symptom score linked to sarcopenia risk and poor functional outcomes.
  3. Williams GR, Al-Obaidi M, Dai C, et al. SARC-F for Screening of Sarcopenia AmongOlder Adults With Cancer. Journal of Geriatric Oncology. 2021;12(1):146-150.Useful because it clearly describes the five SARC-F components and the 0-to-2 scoring structure.
30-Second Chair Stand Test3 references
  1. Jones CJ, Rikli RE, Beam WC. A 30-s Chair-Stand Test as a Measure of Lower Body Strength in Community-ResidingOlder Adults. Research Quarterly for Exercise and Sport. 1999;70(2):113-119.Core validation paper. The authors concluded that the 30-second chair stand is a reasonably reliable and valid indicator of lower-body strength in generally active, community-dwelling older adults.
  2. Centers for Disease Control and Prevention. STEADI Assessment: 30-Second Chair Stand.CDC fall-risk assessment protocol. Supports the practical setup: straight-backed chair without arms, approximately 17-inch seat height, arms crossed, and counting full stands completed in 30 seconds.
  3. Lein DH Jr, Alotaibi M, Almutairi M, Singh H. Normative Reference Values and Validity for the 30-Second Chair-Stand Test in Healthy Young Adults. International Journal of Sports Physical Therapy. 2022;17(5):907-914.Not central for older adults, but useful because it confirms the broader validity and portability of the 30-second chair stand as a functional performance test.